0001171843-25-001863 | 10-K | XBRL Viewer

Inventory Disclosure [Text Block]

NOTE 5 – INVENTORIES

Inventory balances were as follows:

	As of December 31, 2024		As of December 31, 2023
Raw materials	$	175,177	$	227,110
Work-in-process		18,500		-
Finished goods		192,051		253,693
Total	$	385,728	$	480,803

Note 14 - Loss Per Share

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Text Block]

NOTE 14 – LOSS PER SHARE

The following table presents the shares used in the basic and diluted loss per common share computations:

	Year Ended December 31,
	2024			2023
Numerator:
Net (loss) from continuing operations	$	(10,860,205	)	$	(12,017,561	)
Net (loss) from discontinued operations		(1,804,183	)		(1,966,406	)
Net loss attributable to common stockholders	$	(12,664,388	)	$	(13,983,967	)

Denominator:
Weighted average common shares outstanding - basic		5,453,632			4,014,848
Dilutive effect of stock options, warrants and preferred stock (1)		-			-
Weighted average common shares outstanding - diluted		5,453,632			4,014,848

Net (loss) from continuing operations attributable to common stockholders per common share – basic and diluted	$	(1.99	)	$	(2.99	)
Net (loss) from discontinued operations attributable to common stockholders per common share – basic and diluted		(0.33	)		(0.49	)
(Loss) per common share - basic and diluted		(2.32	)		(3.48	)

(1)

The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

	Year Ended December 31,
	2024		2023
Options		43,595		47,664
Warrants		2,750,429		1,806,589
Preferred stock: Series B		16		16

Note 4 - Fair Value Measurements - Fair Value, Assets Measured on Recurring Basis (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Derivatives	$ 0	$ 1,376
Fair Value, Recurring [Member]
Derivatives	0	1,376
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Derivatives	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Derivatives	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Derivatives	0	$ 1,376
Fair Value, Recurring [Member] \| Money Market Funds [Member]
Money market funds	300,000
Fair Value, Recurring [Member] \| Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Money market funds	300,000
Fair Value, Recurring [Member] \| Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Money market funds	0
Fair Value, Recurring [Member] \| Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Money market funds	$ 0

Note 12 - Income Taxes

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Text Block]

NOTE 12 – INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Company incurred zero income tax expense from continuing operations during the years ended December 31, 2024, and 2023, due to losses in both years.

Actual income tax benefit from continuing operations differs from statutory federal income tax benefit as follows:

	Year Ended December 31,
	2024			2023
Statutory federal income tax benefit	$	2,280,643		$	2,523,688
State tax benefit, net of federal taxes		406,186			515,593
State rate adjustment		(24,434	)		(125,150	)
Nondeductible/nontaxable items		(10,951	)		121,708
NOL and deferred only adjustments		(571,133	)		(59,913,532	)
Other		(6,641	)		(5,182	)
Change in valuation allowance		(2,073,670	)		56,882,875
Total income tax benefit	$	-		$	-

Deferred taxes consist of the following:

	December 31, 2024			December 31, 2023
Deferred tax assets:
Compensation accruals	$	42,893		$	87,131
Accruals and reserves		191,804			204,083
Deferred revenue		80,005			36,169
Charitable contribution carryover		1,742			1,724
Derivatives		-			349
Intangibles		696,622			852,414
Capitalized R&D		1,016,330			919,789
Depreciation		-			59,511
Lease liabilities		551,917			703,026
NQSO compensation		542,609			627,997
NOL and credits		24,479,583			21,737,285
Total deferred tax assets		27,603,505			25,229,478

Deferred tax liabilities:
Depreciation		(31,863	)		-
Lease right-of-use assets		(513,256	)		(691,119	)
Total deferred tax liabilities		(545,119	)		(691,119	)

Net deferred tax assets		27,058,386			24,538,359
Less: valuation allowance		(27,058,386	)		(24,538,359	)
Total	$	-		$	-

The Company has determined, based upon its history, that it is probable that future taxable income may be insufficient to fully realize the benefits of the NOL carryforwards and other deferred tax assets. As such, the Company has determined that it is more likely than not that it will not realize its deferred tax assets.

Pursuant to the Internal Revenue Code of 1986, as amended (the “Code”) Sections 382 and 383, annual use of a company’s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.

As of December 31, 2024, the Company had $99,731,593 of NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2025, subject to the Section 382 limitation described above. The federal NOLs of $11,885,918 begin to expire in 2025 if unused and $87,845,675 will carry forward indefinitely. The Company also had $55,735,192 of NOLs to reduce future state taxable income as of December 31, 2024. The state NOLs will begin to expire in 2025 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. As of December 31, 2024, the federal and state valuation allowances were $23,121,946 and $3,936,440, respectively.

During the year-ended December 31, 2023, the Company completed an assessment of the available NOL and tax credit carryforwards under Section 382 and 383 and determined that the Company underwent several ownership changes during the period from 2008 to 2022. The Company adjusted its NOL and tax credit carryforwards to reflect the limitations resulting from the identified ownership changes. The Company reduced its available gross federal and state NOL carryforwards by $237,816,096 and $178,311,455, respectively, and recorded a reduction of $49,941,380 and $7,344,800, respectively, to the federal and state deferred tax asset, each of which related to losses generated for the years ended December 31, 2022, and prior. Accordingly, the NOL and tax credit carryforwards presented above for the year ended December 31, 2023, were reduced by $57,446,259, with a corresponding reduction to the valuation allowance.

As of December 31, 2023, the Company had $86,840,808 of NOLs to reduce future federal taxable income, the majority of which were expected to be available for use in 2024, subject to the Section 382 limitation described above. The federal NOLs of $43,354,286 were to begin to expire in 2024 if unused and $43,486,522 will carry forward indefinitely. The Company also had $59,425,348 of NOLs to reduce future state taxable income as of December 31, 2023. The state NOLs began to expire in 2024. The Company’s net deferred tax assets, which include NOLs are subject to a full valuation allowance. As of December 31, 2023, the federal and state valuation allowances were $20,558,729 and $3,979,630, respectively.

Tax years after 2004 remain open to examination by federal and state tax authorities due to unexpired NOL carryforwards.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. As of December 31, 2024, and 2023, the Company recorded no accrued interest or penalties related to uncertain tax positions.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Note 2 - Discontinued Operations - Schedule of Disposal Groups Including Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Total current assets of discontinued operations	$ 53,649	$ 79,249
Total assets of discontinued operations	0	902,665
Net (loss) from discontinued operations	(1,804,183)	(1,966,406)
Total current liabilities of discontinued operations	164,771	174,839
Birmingham Laboratory [Member] \| Discontinued Operations, Disposed of by Sale [Member]
Revenue	32,790	152,396
Accounts receivable, net	34,853	56,056
Cost of sales	3,295	25,328
Inventories	0	13,571
Gross profit (loss) from discontinued operations	29,495	127,068
Prepaid expense and other assets	18,796	9,622
Total current assets of discontinued operations	53,649	79,249
General and administrative expense	855,855	1,047,578
Property and equipment, net	0	742,696
Operations expense	506,011	859,360
Intangibles, net	0	11,118
Sales and marketing expense	4,385	23,722
Lease right-of-use assets	0	130,264
Loss on impairment of property and equipment	0	162,905
Other long-term assets	0	18,587
Total operating expenses	1,366,251	2,093,565
Total assets of discontinued operations	53,649	981,914
Total operating (loss) from discontinued operations	(1,336,756)	(1,966,497)
Loss on disposal of discontinued operations	(463,127)	0
Accounts payable	0	7,964
Other income (expense)	(4,300)	91
Accrued expenses and other liabilities	75,731	94,345
Net (loss) from discontinued operations	(1,804,183)	(1,966,406)
Lease liability	89,040	72,530
Total current liabilities of discontinued operations	164,771	174,839
Lease liability – net of current portion	0	58,002
Total liabilities	$ 164,771	$ 232,841

Note 11 - Stockholders' Equity, Stock Options and Warrants (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Year Ended December 31,
	2024		2023
	Stock Options
Expected dividend yield		-		0.0%
Expected stock price volatility		-		90.8% –98.2%
Risk-free interest rate		-		3.38% –3.95%
Expected life		-	10 years
	Warrants
Expected dividend yield		0.0%		-
Expected stock price volatility		97.3%		-
Risk-free interest rate		4.06% –4.58%		-
Expected life		1.5 – 5 years		-

Share-Based Payment Arrangement, Activity [Table Text Block]

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding as of December 31, 2023		47,664		$	82.23		1,806,589		$	21.52

Issued		-			-		1,983,302			1.09
Forfeited		(309	)		5.04		-			-
Expired		(3,760	)		83.05		(81,345	)		37.90
Exercised		-			-		(958,117	)		1.32
Outstanding as of December 31, 2024		43,595		$	82.70		2,750,429		$	8.92

Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]

Range of Exercise Prices	Shares		Weighted Average Remaining Life
Options
$6.22 –8.47		810		7.92
$14.65 –25.00		12,158		5.97
$26.20 –32.80		14,223		3.90
$52.20 –17,250.00		16,404		3.69
Total		43,595

Warrants:
$1.07 –1.65		1,983,302		2.88
$14.00 –25.00		462,336		0.14
$27.40 –40.00		226,448		3.26
$43.75 –125.00		78,343		1.03
Total		2,750,429

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]

Year	Shares		Range of Exercise Prices
2015		12	$	30.80	–	$	17,250.00
2016		276		30.80	–		850.00
2017		10,353		30.80	–		420.00
2018		2,893		30.80	–		226.00
2019		13,932		30.80	–		158.00
2020		14,710		14.65	–		32.80
2021		540		25.00	–		26.60
2022		729		7.70	–		14.65
2023		150		6.22	–		6.22
Total		43,595	$	6.22	–	$	17,250.00

Year	Shares		Range of Exercise Prices
2019		3,168	$	125.00	–	$	125.00
2020		65,586		36.00	–		59.84
2021		603,353		16.00	–		48.75
2022		95,020		14.00	–		15.00
2023		-		-	–		-
2024		1,983,302		1.07	–		1.65
Total		2,750,429	$	1.07	–	$	125.00

Note 15 - Segments (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Year Ended December 31, 2024
	Pittsburgh			Eagan			Corporate			Total
Revenue	$	84,812		$	1,539,005		$	-		$	1,623,817
Cost of sales		78,285			747,852			-			826,137
Gross profit		6,527			791,153			-			797,680
General and administrative expenses		2,022,732			184,095			5,213,065			7,419,892
Operations expenses		2,234,501			609,584			6,960			2,851,045
Sales and marketing expenses		5			633,015			833,193			1,466,213
Total operating (loss)		(4,250,711	)		(635,541	)		(6,053,218	)		(10,939,470	)
Other segment items		(606	)		(9	)		79,880			79,265
Segment (loss)	$	(4,251,317	)	$	(635,550	)	$	(5,973,338	)	$	(10,860,205	)

	December 31, 2024
	Pittsburgh		Eagan		Corporate		Total
Assets	$	2,615,291	$	1,410,090	$	893,487	$	4,918,868
Depreciation and amortization		124,939		29,743		7,397		162,079
Expenditures for additions to long-lived assets		3,032		6,478		-		9,510

	Year Ended December 31, 2023
	Pittsburgh			Eagan			Corporate			Total
Revenue	$	492,596		$	1,135,101		$	-		$	1,627,697
Cost of sales		195,105			414,107			-			609,212
Gross profit		297,491			720,993			-			1,018,485
General and administrative expenses		2,364,640			518,017			5,498,260			8,380,917
Operations expenses		2,443,316			806,658			18,192			3,268,165
Sales and marketing expenses		299			364,697			1,122,142			1,487,139
Total operating (loss)		(4,510,763	)		(968,379	)		(6,638,594	)		(12,117,736	)
Other segment items		6,857			(902	)		94,220			100,175
Segment (loss)	$	(4,503,906	)	$	(969,281	)	$	(6,544,374	)	$	(12,017,561	)

	December 31, 2023
	Pittsburgh		Eagan		Corporate		Total
Assets	$	3,263,270	$	1,390,031	$	8,782,034	$	13,435,335
Depreciation and amortization		207,658		29,750		7,381		244,788
Expenditures for additions to long-lived assets		7,424		24,691		15,437		47,550

Note 4 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2024

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

December 31, 2024	Fair Value		Level 1		Level 2		Level 3
Assets:
Money market funds	$	300,000	$	300,000	$	-	$	-

Liabilities:
Derivatives	$	-	$	-	$	-	$	-

December 31, 2023	Fair Value		Level 1		Level 2		Level 3
Liabilities:
Derivatives	$	1,376	$	-	$	-	$	1,376

Note 14 - Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended December 31,
	2024			2023
Numerator:
Net (loss) from continuing operations	$	(10,860,205	)	$	(12,017,561	)
Net (loss) from discontinued operations		(1,804,183	)		(1,966,406	)
Net loss attributable to common stockholders	$	(12,664,388	)	$	(13,983,967	)

Denominator:
Weighted average common shares outstanding - basic		5,453,632			4,014,848
Dilutive effect of stock options, warrants and preferred stock (1)		-			-
Weighted average common shares outstanding - diluted		5,453,632			4,014,848

Net (loss) from continuing operations attributable to common stockholders per common share – basic and diluted	$	(1.99	)	$	(2.99	)
Net (loss) from discontinued operations attributable to common stockholders per common share – basic and diluted		(0.33	)		(0.49	)
(Loss) per common share - basic and diluted		(2.32	)		(3.48	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Year Ended December 31,
	2024		2023
Options		43,595		47,664
Warrants		2,750,429		1,806,589
Preferred stock: Series B		16		16

Note 8 - Leases - Lease Information (Details)	Dec. 31, 2024	Dec. 31, 2023
Weighted average remaining lease term – operating leases in years (Year)	3 years 1 month 20 days	4 years 1 month 9 days
Weighted average discount rate – operating leases	13.00%	13.00%

Note 10 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) (Parentheticals)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	(Gain) on derivative instruments	(Gain) on derivative instruments

Note 6 - Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Table Text Block]

	As of December 31, 2024			As of December 31, 2023
Computers, software, and office equipment	$	237,726		$	467,716
Leasehold improvements		306,961			306,961
Laboratory equipment		1,692,230			1,696,430
Warehouse and manufacturing equipment		139,763			133,285
Demo equipment		31,554			31,554
Total		2,408,234			2,635,946
Less: Accumulated depreciation		(2,038,764	)		(2,144,732	)
Total Property and equipment, net	$	369,470		$	491,214

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Nature Of Operations and Going Concern Policy [Policy Text Block]

Nature of Operations

Predictive Oncology Inc. (“Predictive Oncology” or the “Company”) is a knowledge-driven company focused on applying artificial intelligence (“AI”) to support the development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses its proprietary biobank of 150,000+ cancer tumor samples, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of successful drug development. The Company offers a suite of solutions for oncology drug development from early discovery to clinical trials.

Predictive Oncology’s mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer. By harnessing the power of machine learning and scientific rigor, the Company believes that it can improve the probability of success of advancing pharmaceutical and biological drug candidates with a higher degree of confidence.

During the year ended December 31, 2024, the Company’s former Birmingham operating segment, which provided contract services and research focused on solubility improvements, stability studies and protein production, met the criteria to be reported as discontinued operations. As a result, the Company operated in two remaining business areas as of December 31, 2024. In its first area, the Company provides optimized, high-confidence drug-response predictions through the application of AI using its proprietary biobank of tumor samples to enable a more informed selection of drug/tumor combinations and increase the probability of success during drug development. The Company also creates and develops tumor-specific 3D cell culture models mimicking the physiological environment of human tissue enabling better-informed decision-making during development. In its second business area, the Company produced the United States Food and Drug Administration (“FDA”)-cleared STREAMWAY® System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

As a result of the decision to discontinue its former Birmingham operating segment, the Company had two reportable segments as of December 31, 2024, which were delineated by location and business area, as further described in Note 15 – Segments:

●

Pittsburgh segment: provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. Pittsburgh also creates proprietary 3D culture models used in drug development.

●

Eagan segment: produced the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

On January 1, 2025, the Company entered into a binding letter of intent (the “LOI”) with Renovaro, Inc. (NASDAQ: RENB) (“Renovaro”) for Predictive Oncology to be acquired by Renovaro in exchange for preferred stock of Renovaro (the “Renovaro Merger”). Under the terms of the LOI, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock, as further discussed in Note 16 – Subsequent Events.

On February 28, 2025, Predictive Oncology entered into an extension agreement with Renovaro (the “Extension Agreement”), pursuant to which the parties amended certain terms of the LOI, including to extend the outside termination date of the LOI from February 28, 2025, to March 31, 2025, as further discussed in Note 16 – Subsequent Events.

On March 14, 2025, the Company entered into an asset purchase agreement and closed the transactions contemplated therein with DeRoyal Industries, Inc., a Tennessee corporation (“DeRoyal”), to sell and assign to DeRoyal assets and liabilities exclusively related to the business of providing products for automated, direct-to-drain medical fluid disposal, including the Company’s STREAMWAY® product line. Refer to Note 16 – Subsequent Events for further discussion of the asset purchase agreement with DeRoyal. The assets subject to the asset purchase agreement were operated by and reported in the Company’s Eagan reportable operating segment. The Eagan operating segment did not meet the criteria under US GAAP to be reported as discontinued operations as of and for the year ended December 31, 2024. Therefore, the Eagan operating segment is reported within continuing operations in these consolidated financial statements.

Going Concern

These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

The Company has incurred significant and recurring losses from operations for the past several years and, as of December 31, 2024, had an accumulated deficit of $180,426,271. The Company had cash and cash equivalents of $734,673 as of December 31, 2024, and needs to raise significant additional capital to meet its operating needs. The Company had short-term obligations of $3,593,401 and long-term operating lease obligations of $1,558,239 as of December 31, 2024. The Company does not expect to generate sufficient operating revenue to sustain its operations in the near term. During the year ended December 31, 2024, the Company incurred negative cash flows from continuing operating activities of $10,974,568. Although the Company has attempted to improve its cash flows from continuing operating activities by bolstering revenues and continues to seek ways to generate revenue through business development activities, there is no guarantee that the Company will be able to improve its cash flows from continuing operating activities sufficiently or achieve profitability in the near term. As a result of these conditions, substantial doubt exists about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued.

The Company continues to evaluate alternatives to obtain the required additional funding to maintain future operations, including the Renovaro Merger and the Sale of Eagan Assets to DeRoyal (further detailed in Note 16 – Subsequent Events). These alternatives may include, but are not limited to, equity financing, issuing debt, entering into other financing arrangements, or monetizing operating businesses or assets. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing stockholders or that result in the Company’s existing stockholders losing part or all of their investment. Despite these potential sources of funding, the Company may be unable to access financing or obtain additional liquidity when needed or under acceptable terms, if at all. If such financing or adequate funds from operations are not available, the Company would be forced to limit its business activities and the Company could default on existing payment obligations, which would have a material adverse effect on its financial condition and results of operations, and the Company may ultimately be required to cease its operations and liquidate its business. The consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.

NASDAQ Notice of Non-compliance, Policy [Policy Text Block]

NASDAQ Notice of Non-Compliance

On September 19, 2024, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock had closed below $1.00 per share for 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notification had no immediate effect on the listing of the Company’s common stock and the Company had a period of 180 calendar days, or until March 18, 2025, to regain compliance with the Minimum Bid Price Requirement. On January 22, 2025, the Company received a letter from the Staff of the Nasdaq indicating that the closing bid price of the Company’s common stock had been at $1.00 per share or greater for the last 11 consecutive business days, from January 3, through 21, 2025. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement.

On November 20, 2024, the Company received a letter (the “Notice”) from the Staff of the Nasdaq notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), because the Company’s stockholders’ equity of $1,966,969, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, was below the required minimum of $2.5 million, and because, as of the date of the Notice, the Company did not meet either of the alternative compliance standards, relating to market value of listed securities of at least $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.

The Notice had no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market, and, therefore, the Company’s listing remains fully effective, subject to the Company’s compliance with the other continued listing requirements, and the Company’s regaining compliance with the Stockholders’ Equity Requirement. Under Nasdaq rules and as specified in the Notice, the Company had 45 calendar days from November 20, 2024, or until Monday, January 6, 2025, to submit to Nasdaq a plan to regain compliance with the Stockholders’ Equity Requirement. If the Company’s plan to regain compliance was accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to evidence compliance.

On January 6, 2025, the Company submitted to Nasdaq a plan to regain compliance with the Stockholders’ Equity Requirement, citing the Company’s proposed merger with Renovaro, and requested a 180-day extension to regain compliance with the Stockholders’ Equity Requirement. In response, the Nasdaq requested upon execution, or by no later than March 1, 2025, a copy of the definitive merger documentation and a detailed timeline to complete the merger. On February 28, 2025, the Company notified the Staff that the Company continues to progress in discussions with Renovaro to finalize the merger. The Company also notified the Staff of the Extension Agreement entered into with Renovaro on February 28, 2025, which extended the outside termination date from February 28, 2025, to March 31, 2025.

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

The Company has prepared the consolidated financial statements in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”) for consolidated financial statements.

The Company had two wholly owned subsidiaries, Helomics Corporation and Skyline Medical Inc. (“Skyline Medical”), as of and for the years ended December 31, 2024, and 2023. The consolidated financial statements include the accounts of the Company and these wholly owned subsidiaries after elimination of intercompany transactions and balances as of and for the years ended December 31, 2024, and 2023.

Discontinued Operations, Policy [Policy Text Block]

Discontinued Operations

During the year ended December 31, 2024, the Company disposed of its former Birmingham operating segment. Disposal groups that meet the discontinued operations criteria provided in the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 205-20-45 are classified as discontinued operations. Assets and liabilities of discontinued operations are presented separately in the Company’s consolidated balance sheets and results of discontinued operations are reported as a separate component of net loss in the Company’s consolidated statements of net loss for all periods presented, resulting in changes to the presentation of certain prior period amounts. Results of discontinued operations are excluded from segment results for all periods presented. Cash flows from discontinued operations are also reported separately in the Company’s consolidated statements of cash flows.

Refer to Note 2 – Discontinued Operations for additional discussion of discontinued operations. All other notes to these consolidated financial statements present the results of continuing operations and exclude amounts related to discontinued operations for all periods presented.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Estimates are used in the following areas, among others: variable consideration associated with revenue recognition, stock-based compensation expense, fair value of long-lived assets for impairment analyses, the valuation allowance included in the deferred income tax calculation, accrued expenses, and fair value of derivative liabilities.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

The Company considers all highly liquid instruments with maturities when purchased of three months or less to be cash equivalents. The Company places its cash with high quality financial institutions and believes its risk of loss is limited to amounts in excess of that which is insured by the Federal Deposit Insurance Corporation.

Receivable [Policy Text Block]

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts.

Amounts recorded in accounts receivable on the consolidated balance sheets include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance is maintained to provide for the estimated amount of receivables that will not be collected. The Company determines the allowance based on historical experience as well as external business factors expected to impact collectability such as economic factors. The Company reviews customers’ credit history before extending unsecured credit and establishes an allowance based upon factors surrounding the credit risk of specific customers, historical trends, and other information. Invoices are generally due 30 days after presentation. Accounts receivable over 30 days is generally considered past due. The Company does not accrue interest on past due accounts receivables. Receivables are written off once all collection attempts have failed and are based on individual credit evaluation and specific circumstances of the customer.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalent balances with high quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

As outlined in ASC 820, Fair Value Measurement, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC 820 establishes a three-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data in making fair value measurements, when available. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair values of the Company’s derivative liabilities were determined based on Level 3 inputs. The Company generally uses the Black Scholes method for determining the fair value of warrants classified as liabilities on a recurring basis. In addition, the Company uses the Monte Carlo method and other acceptable valuation methodologies when valuing the conversion feature and other embedded features classified as derivatives on a recurring basis. See Note 4 – Fair Value Measurements and Note 10 – Derivatives.

When comparing the carrying amount of an asset group to its fair value as part of a long-lived asset impairment analysis, the Company estimates the fair value of the asset group by making assumptions about the long-lived assets comprising the asset group. The majority of the inputs used by the Company to estimate the fair value of the long-lived assets are unobservable and thus are considered to be Level 3 inputs. See Note 6 – Property and Equipment and Note 7 – Intangible Assets.

Inventory, Policy [Policy Text Block]

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers, software, and office equipment	3	-	10
Leasehold improvements (1)	1	-	2
Manufacturing tooling	3	-	7
Laboratory equipment	4	-	10
Demo equipment		3

(1)

Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Upon retirement or sale of property and equipment, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Finite-lived Intangible Assets

Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, acquired software, customer relationships, and tradenames, and are amortized over their estimated useful life. Accumulated amortization is included in Intangibles, net in the accompanying consolidated balance sheets.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-lived Assets

The Company reviews long-lived assets for impairment in accordance with ASC 360, Property, Plant and Equipment, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

The recoverability of an asset to be held and used is determined by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated undiscounted future cash flows, the Company records an impairment charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if any, or a value determined utilizing discounted cash flow techniques.

Lessee, Leases [Policy Text Block]

Leases

At inception of a contract a determination is made whether an arrangement meets the definition of a lease. A contract contains a lease if there is an identified asset, and the Company has the right to control the asset. Operating leases are recorded as right-of-use (“ROU”) assets with corresponding current and noncurrent operating lease liabilities on our consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 months or less at the commencement date are not recognized on the consolidated balance sheet and are expensed as incurred.

The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Variable lease payments generally represent the Company’s share of the landlord’s expenses and are recorded when incurred. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.

Collaborative Arrangement, Accounting Policy [Policy Text Block]

Collaboration Arrangements

The Company enters into collaboration arrangements with oncology drug development partners, under which the Company utilizes its active learning technology, proprietary biobank, and know-how to provide predictive models of tumor responses to various drug compounds and treatments of partners. Consideration under these contracts may include an upfront payment, development and regulatory milestones and other contingent payments, expense reimbursements, royalties based on net sales of approved drugs, and commercial sales milestone payments.

The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements, which includes determining whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. To the extent that the arrangement falls within the scope of ASC 808, the Company assesses whether the payments between the Company and its collaboration partner fall within the scope of other accounting literature. If the Company concludes that payments from the collaboration partner to the Company would represent consideration from a customer, the Company accounts for those payments within the scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. However, if the Company concludes that its collaboration partner is not a customer for certain activities and associated payments, the Company presents such payments as a reduction of research and development expense or general and administrative expense, based on where the Company presents the underlying expense.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company recognizes revenue in accordance with the five-step process outlined in ASC 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amount to the governmental authorities. Sales taxes are excluded from revenue and expenses. Advertising costs incurred in the Company’s efforts to obtain new customers are expensed as incurred.

Revenues from Services

The Company generates revenues from Contract Research Organization (“CRO”) services related to the development of 3D tumor-specific in vitro models for oncology drug discovery and research. The organ-specific disease models provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response. Revenue from development of 3D models is reported under the Pittsburgh reportable segment.

The specific pattern of revenue recognition for CRO services is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company may execute a master service agreement with a customer that provides terms and conditions for the relationship between the Company and the customer. Detailed Statements of Work (SOWs) are then prepared to outline the specific services to be provided. The SOW and master service agreement, if applicable, form the contract with the customer under ASC 606. The Company evaluates each product or service promised in a contract to determine whether it represents a distinct performance obligation. Determining whether services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Contracts for CRO services generally contain one performance obligation to perform research and deliver appropriate data or reporting. The Company typically requires partial payment for CRO services prior to performance of the research service with the remainder of the transaction price due 30 days after delivery of data or reporting. Revenues from CRO services are generally recognized at the point in time when data and reports are provided to customers.

The Company also generates revenues from services provided under maintenance plans related to the Company’s STREAMWAY System. Customers may purchase maintenance plans, which require the Company to service the customer’s STREAMWAY System for a period of one year. Payment due under the maintenance plan is typically due at the start of the service period. The maintenance plan is considered a separate performance obligation from the sale of the STREAMWAY System, is charged separately from the product sale, and is recognized over time (ratably over the one-year period) as maintenance services are provided. A time-elapsed output method is used to measure progress toward complete satisfaction of the performance obligation because the Company transfers control evenly by providing a stand-ready service. The Company has determined that this method provides a faithful depiction of the transfer of services to its customers. Revenues from maintenance plans related to the Company’s STREAMWAY System are reported under the Eagan reportable segment.

Revenues from Product Sales

The Company generates revenues from the sale of medical device products consisting primarily of sales of the STREAMWAY System (i.e., hardware), as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System (i.e., disposables). Currently, the Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The sales agreement is a dually executed agreement providing explicit terms and conditions supporting the sale of the STREAMWAY System and related products and services. The Company considers the combination of a purchase order and sales agreement providing its terms and conditions to form the contract with the customer in all cases.

Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time following the transfer of control of such products to the customer. Transfer of control may occur when products are shipped from the Company’s facilities (“FOB origin,” which is the Company’s standard shipping terms) or upon delivery at the customer’s facilities (“FOB Destination”), dependent on the shipping terms specified in the contract with the customer. Transfer of control may also occur prior to shipment under bill and hold arrangements. In such arrangements, the Company recognizes revenue when the bill-and-hold arrangement has a substantive reason, the product is identified separately as belonging to the customer, the product is ready for physical transfer to the customer, and the Company does not have the ability to use the product or direct it to another customer. The Company’s standard payment terms for its customers purchasing medical devices are generally 30 to 60 days after the Company transfers control of the product to its customer. The Company allows returns of defective disposable merchandise if the customer requests a return merchandise authorization from the Company. All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Revenues from the sale of medical device products are reported under the Eagan reportable segment.

Royalty Revenue and Variable Consideration

The Company has a collaboration arrangement that includes sales-based royalties, under which our collaboration partner is obligated to pay revenue sharing fees that are based on the net sales of the collaboration partner’s commercialized drugs. The Company would recognize royalty revenue when the underlying sales occur based on its best estimate of sales of the drugs. To date, the Company has not recognized revenues related to revenue sharing fees pursuant to its collaboration arrangement. See Note 11 – Collaboration Agreement.

Warranty

The Company generally provides one-year warranties against defects in materials and workmanship on product sales and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, the Company does not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect.

Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Advance payments received in excess of revenues recognized are classified as contract liabilities until such time as the revenue recognition criteria have been met.

Practical Expedients

The Company has elected not to determine whether contracts with customers contain significant financing components as contracts are generally for less than one year. The Company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. The Company recognizes shipping and handling costs at point of sale.

Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

The Company accounts for stock-based compensation expense in accordance with ASC 718, Compensation—Stock Compensation, which requires the Company to measure and recognize compensation expense in the financial statements based on the fair value at the date of grant for stock-based awards. The Company recognizes compensation expense for service-based equity-classified awards over their requisite service period and adjusts for forfeitures as they occur.

ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model which requires the input of significant assumptions including an estimate of the average period of time employees and directors will retain vested stock options before exercising them, the estimated volatility of the Company’s common stock price over the expected term, and the risk-free interest rate.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason, the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period that investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company’s common stock price over the expected term, and the risk-free interest rate. In the case of options granted to employees, the Company estimates the life to be the legal term.

Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognizes that. The Company’s common stock has been traded on the NASDAQ Capital Market exchange since 2015 and the Company has experienced significant volatility in its stock price. The assumptions used in calculating the fair value of stock-based payment awards represent the Company’s best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, its stock-based compensation expense could be materially different in the future.

The Company has a sequencing policy under ASC 815-40-35 (“ASC 815”) that will apply if reclassification of contracts from equity to liabilities is necessary. If the Company is unable to demonstrate it has sufficient authorized shares, shares will be allocated based on the earliest issuance date of potentially dilutive financial instruments, with the earliest financial instruments receiving the first allocation of shares. Pursuant to ASC 815, stock-based awards issued to the Company’s employees are not subject to the sequencing policy.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations as incurred. Research and development costs, included within operations expense in the accompanying consolidated statements of net loss were $25,987 and $122,307 for the years ended December 31, 2024, and 2023, respectively.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

Under Internal Revenue Code Section 382, certain stock transactions that significantly change ownership could limit the amount of net operating carryforwards that may be utilized on an annual basis to offset taxable income in future periods. Consequently, the Company performed a Section 382 analysis as of December 31, 2023, which resulted in the limitation and expiration of a substantial portion of the Company’s loss carryforwards. In addition, the current net operating loss (“NOL”) carryforwards might be further limited by future issuances of our common stock. See Note 12 – Income Taxes.

Tax years after 2004 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

Risk and Uncertainties [Policy Text Block]

Risks and Uncertainties

The Company is subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the Food and Drug Administration, Clinical Laboratory Improvement Amendments, and other governmental agencies.

The Company is also subject to general economic and geopolitical uncertainties caused by inflation, rising interest rates, supply chain disruptions, tight labor markets, wage inflation, pricing volatility for certain goods and services, banking and financial sector disruptions, instability and volatility in the global markets, disruptions from a global pandemic, and geopolitical conflict. The impacts of economic and other global events could have a material adverse effect on our business, results of operations, liquidity or financial condition and heighten or exacerbate risks related to the Company.

The Company has evaluated all its activities and concluded that no other subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes to the consolidated financial statements, except as described above and in Note 16 – Subsequent Events.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the FASB. Recently issued ASUs not listed below either were assessed and determined to be not applicable or are currently expected to have no impact on the consolidated financial statements of the Company.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires more detailed income tax disclosures. The guidance requires entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. Management is currently evaluating this ASU to determine its impact on the Company’s disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures related to certain costs and expenses. The guidance requires entities to disclose amounts of certain expense categories included in expense captions presented on the face of the income statement, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The disclosure requirements may be applied either prospectively or retrospectively. Management is currently evaluating this ASU to determine its impact on the Company’s disclosures.

Recently Adopted Accounting Standards

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU updates reportable segment disclosures by expanding the frequency and extent of segment disclosures. This ASU is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The ASU requires the retrospective adoption method. The Company adopted ASU 2023-07 for annual periods beginning in the fiscal year ending December 31, 2024. The company plans to adopt ASU 2023-07 for interim periods beginning in the fiscal year ending December 31, 2025. See Note 15 to these consolidated financial statements for additional discussion.

Note 14 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Net (loss) from continuing operations

$ (10,860,205)

$ (12,017,561)

Loss from discontinued operations

(1,804,183)

(1,966,406)

Net loss attributable to common stockholders

$ (12,664,388)

$ (13,983,967)

Weighted average shares used in computation – basic and diluted (in shares)

5,453,632

4,014,848

Dilutive effect of stock options, warrants and preferred stock (1) (in shares)

^[1]

Weighted average common shares outstanding - diluted (in shares)

5,453,632

4,014,848

Loss from continuing operations (in dollars per share)

$ (1.99)

$ (2.99)

Net (loss) from discontinued operations attributable to common stockholders per common share – basic and diluted (in dollars per share)

(0.33)

(0.49)

(Loss) per common share - basic and diluted (in dollars per share)

$ (2.32)

$ (3.48)

[1]	The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Amount after tax of income (loss) from continuing operations attributable to the parent.

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(13))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References + Details

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares outstanding (in shares)	6,666,993	4,062,853
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares outstanding (in shares)	79,246	79,246

Note 7 - Intangibles, Net

12 Months Ended

Dec. 31, 2024

Intangible Assets Disclosure [Text Block]

NOTE 7 – INTANGIBLES, NET

The Company’s intangibles, net consisted of the following:

	As of December 31, 2024							As of December 31, 2023
	Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount		Gross Carrying Costs		Accumulated Amortization			Net Carrying Amount
Patents & Trademarks	$	515,948	$	(305,835	)	$	210,113	$	521,621	$	(280,282	)	$	241,339

Finite-lived intangible assets are amortized over their estimated useful lives. Amortization expense, recorded within general and administrative expenses of continuing operations, was $26,488 and $26,463 during the years ended December 31, 2024, and 2023, respectively. Accumulated amortization is included in Intangibles, net in the consolidated balance sheets.

The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2024:

Year Ending December 31,	Expense
2025	$	26,489
2026		26,489
2027		26,489
2028		26,489
2029		26,489
Thereafter		77,669
Total	$	210,113

The Company reviews finite-lived intangible assets for impairment in accordance with ASC 360, Property, Plant, and Equipment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates. No impairment charges related to finite-lived intangible assets held and used in continuing operations were incurred during the years ended December 31, 2024, and 2023.

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Property Plant and Equipment Useful Life [Table Text Block]

	Years
Computers, software, and office equipment	3	-	10
Leasehold improvements (1)	1	-	2
Manufacturing tooling	3	-	7
Laboratory equipment	4	-	10
Demo equipment		3

Note 7 - Intangibles, Net - Components of Intangible Assets (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Net Carrying Amount	$ 210,113
Patents and Trademarks [Member]
Gross Carrying Costs	515,948	$ 521,621
Accumulated Amortization	(305,835)	(280,282)
Net Carrying Amount	$ 210,113	$ 241,339

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Cash flow from operating activities:
Net loss	$ (12,664,388)	$ (13,983,967)
Loss from discontinued operations	(1,804,183)	(1,966,406)
Net loss from continuing operations	(10,860,205)	(12,017,561)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	162,079	244,788
Amortization of operating lease right-of-use assets	533,584	480,020
Vesting expense	1,118	1,167
Common stock issued for consulting and other	99,253	299,430
(Gain) on derivative instruments	(1,376)	(12,457)
Loss on disposal of property and equipment	803	903
Loss on disposal of intangible assets	4,738	0
Changes in assets and liabilities:
Accounts receivable	(467,925)	19,003
Inventories	95,075	(65,448)
Prepaid expense and other assets	208,776	(41,146)
Accounts payable	(191,145)	399,207
Accrued expenses and other	(134,961)	(384,149)
Contract liabilities	2,486	(266,803)
Operating lease liability	(444,896)	(446,483)
Other long-term liabilities	18,028	5,459
Net cash (used in) continuing operating activities:	(10,974,568)	(11,784,070)
Cash flow from continuing investing activities:
Purchase of property and equipment	(9,510)	(21,533)
Acquisition of intangibles	0	(26,017)
Net cash (used in) continuing investing activities:	(9,510)	(47,550)
Cash flow from continuing financing activities:
Proceeds from issuance of common stock and warrants	4,960,562	0
Costs to issue common stock and warrants	(870,960)	0
Repurchase of common stock upon vesting of restricted stock units	0	(1,509)
Proceeds from issuance of financing note payable	275,098	364,721
Repayment of note payable	(425,506)	(214,313)
Net cash provided by continuing financing activities	3,939,194	148,899
Discontinued operations:
Net cash (used in) operating activities	(981,103)	(1,405,321)
Net cash provided by (used in) investing activities	32,000	(254,821)
Net cash provided by (used in) financing activities	0	0
Net cash (used in) discontinued operations	(949,103)	(1,660,142)
Net (decrease) in cash	(7,993,987)	(13,342,863)
Cash and cash equivalents at beginning of period	8,728,660	22,071,523
Cash and cash equivalents at end of period	734,673	8,728,660
Supplemental disclosure for cash flow information:
Cash payments for interest	11,466	13,904
Equipment transferred from discontinued operations	5,140	0
Right-of-use assets obtained in exchange for lease liabilities	0	2,997,181
Series F Preferred Stock dividend	0	794
Common stock issued	0	189,896
Redemption of Series F Preferred Stock	0	794
Redemption of Series F Preferred Stock	0	(794)
Reverse Stock Split [Member]
Supplemental disclosure for cash flow information:
Common stock issued	0	253
Restricted Stock Units (RSUs) [Member]
Supplemental disclosure for cash flow information:
Common stock issued	$ 0	$ 4,934

Note 8 - Leases

12 Months Ended

Dec. 31, 2024

Lessee, Operating Leases [Text Block]

NOTE 8 – LEASES

The Company’s corporate offices and other offices are located in Pittsburgh, Pennsylvania. The leases are effective through February 29, 2028.

The Company also has an office in Eagan, Minnesota, which is used for office space and manufacturing. This lease is effective through May 31, 2025.

Lease expense under operating lease arrangements, recorded within general and administrative expenses of continuing operations, was $827,363 and $811,090 for the years ended December 31, 2024, and 2023, respectively.

The following table summarizes other information related to the Company’s operating leases used in continuing operations:

	December 31, 2024			December 31, 2023
Weighted average remaining lease term – operating leases in years		3.14			4.11
Weighted average discount rate – operating leases		13	%		13	%

The Company’s operating lease obligations as of December 31, 2024, which include expected lease extensions that are reasonably certain of renewal, were as follows:

2025		798,262
2026		803,724
2027		827,909
2028		139,022
Total lease payments		2,568,917
Less: interest		(437,939	)
Present value of lease liabilities	$	2,130,978

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jan. 01, 2025	Sep. 30, 2024 USD ($)	Dec. 31, 2022 USD ($)
Number of Tumor Samples	150,000
Number of Operating Segments	2
Number of Reportable Segments	2
Retained Earnings (Accumulated Deficit)	$ (180,426,271)	$ (167,761,883)
Cash and Cash Equivalents, at Carrying Value	734,673	8,728,660
Liabilities, Current	3,593,401	3,951,031
Operating Lease, Liability, Current	1,558,239	2,130,977
Net Cash Provided by (Used in) Operating Activities	(10,974,568)	(11,784,070)
Equity, Attributable to Parent	(202,610)	8,271,780		$ 1,966,969	$ 21,765,892
Research and Development Expense, Total	25,987	$ 122,307
Unrecognized Tax Benefits	$ 0
Renovaro Acquisition [Member] \| Renovaro Preferred Stock [Member]
Business Acquisition, Equity Interest Issued and Issuable, Exchange Rate			1

Note 5 - Inventories (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Inventory, Current [Table Text Block]

	As of December 31, 2024		As of December 31, 2023
Raw materials	$	175,177	$	227,110
Work-in-process		18,500		-
Finished goods		192,051		253,693
Total	$	385,728	$	480,803

Note 11 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Warrants, outstanding (in shares)	1,806,589
Warrants, average exercise price (in dollars per share) \| $ / shares	$ 21.52
Warrants, issued (in shares)	1,983,302
Issued, average exercise price, warrants (in dollars per share) \| $ / shares	$ 1.09
Warrants, forfeited (in shares)	0
Warrants, expired (in shares)	(81,345)
Expired, average exercise price, warrants (in dollars per share) \| $ / shares	$ 37.9
Warrants, Exercised (in shares)	(958,117)
Exercised, Average Exercise Price, Warrants (in dollars per share) \| $ / shares	$ 1.32
Number of Shares Outstanding (in shares)	43,595
Share-Based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	47,664
Average Exercise Price Outstanding (in dollars per share) \| $ / shares	$ 82.23
Number of Shares Issued (in shares)	0
Average Exercise Price Issued (in dollars per share) \| $ / shares	$ 0
Number of Shares Forfeited (in shares)	(309)
Average Exercise Price Forfeited (in dollars per share) \| $ / shares	$ 5.04
Number of Shares Expired (in shares)	(3,760)
Average Exercise Price Expired (in dollars per share) \| $ / shares	$ 83.05
Number of Shares, Exercised (in shares)	0
Average Exercise Price, Exercised (in dollars per share) \| $ / shares	$ 0
Number of Shares Outstanding (in shares)	43,595
Average Exercise Price Outstanding (in dollars per share) \| $ / shares	$ 82.7

Note 8 - Leases (Details Textual) - USD ($)	12 Months Ended
Note 8 - Leases (Details Textual) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Operating Lease, Expense	$ 827,363	$ 811,090

Note 6 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Depreciation	$ 135,591	$ 218,325
Property, Plant and Equipment [Member]
Asset Impairment Charges	$ 0	$ 0

Note 7 - Intangibles, Net (Details Textual) - USD ($)	12 Months Ended
Note 7 - Intangibles, Net (Details Textual) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Amortization of Intangible Assets	$ 26,488	$ 26,463
Impairment of Intangible Assets (Excluding Goodwill)	$ 0	$ 0

Note 16 - Subsequent Events

12 Months Ended

Dec. 31, 2024

Subsequent Events [Text Block]

NOTE 16 – SUBSEQUENT EVENTS

Renovaro Letter of Intent and Extension Agreement

On January 1, 2025, the Company entered into a binding letter of intent with Renovaro for Predictive Oncology to be acquired by Renovaro in exchange for preferred stock of Renovaro, as discussed in Note 1 above. Under the terms of the LOI, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. The preferred stock will be automatically redeemable for $3.00 per share after 18 months and may also be converted to freely tradeable, registered Renovaro common stock at a 1:1 conversion ratio by either the holders thereof or Renovaro at any time after Renovaro’s common stock has traded at or above $4.50 per share for 30 consecutive trading days. Renovaro also will have the right to redeem the preferred stock for cash at a redemption price of $3.00 per share (i) if the trading price of its common stock is $3.00 or less or (ii) such preferred stock has not been converted within 30 days after the first date on which the holder could request such conversion as described above. The merger is subject to a minimum fundraising of $15 million by Renovaro, as well as formal approval by the shareholders of Predictive Oncology. A failure to obtain shareholder approval, assuming prior funding by Renovaro, will entitle Renovaro to a two-year exclusive royalty-free license to Predictive Oncology’s biobank of tumor samples and tumor-specific 3D cell culture models.

On February 28, 2025, the Company entered into the Extension Agreement with Renovaro, pursuant to which the parties amended the LOI to (i) eliminate Renovaro’s obligation to acquire certain shares of Predictive Oncology’s common stock and (ii) extend the outside termination date of the LOI from February 28, 2025, to March 31, 2025. Additionally, pursuant to the Extension Agreement, Renovaro acquired 467,290 shares of Predictive Oncology’s common stock for an aggregate purchase price of $500,000 and agreed to purchase an additional 901,298 shares of Predictive Oncology common stock for an aggregate of $964,389 upon, and subject to, the execution of a definitive agreement in respect of the Renovaro Merger.

February 2025 Registered Direct Offering

On February 18, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors for the sale by the Company of 363,336 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $1.50 per share, in a registered direct offering. The offering closed on February 19, 2025. The gross proceeds to the Company from the offering are approximately $545,004, before deducting the placement agent’s fees and other offering expenses. The Shares were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3, which was filed with the SEC on May 21, 2024 and subsequently declared effective on May 21, 2024 (File No. 333-279123), and a related prospectus supplement filed on February 19, 2025.

The Company agreed to pay Wainwright an aggregate fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in the offering as well as a management fee equal to 1.0% of such gross proceeds, and $15,000 for fees and expenses of legal counsel. The Company also issued to Wainwright or its designees warrants to purchase up to 7.0% of the aggregate number of shares of Common Stock sold in the transactions, or warrants to purchase up to an aggregate of 25,434 shares of Common Stock (the “Registered Direct Offering Placement Agent Warrants”). The Registered Direct Offering Placement Agent Warrants are exercisable for five years from the commencement of sales in the offering and have an exercise price equal to 125% of the purchase price of share of Common Stock in the offering, or $1.875 per share. The Registered Direct Offering Placement Agent Warrants and the shares issuable upon exercise of the Registered Direct Offering Placement Agent Warrants were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws.

Sale of Eagan Assets to DeRoyal

On March 14, 2025, the Company entered into an asset purchase agreement (the “APA”) and closed the transactions contemplated therein with DeRoyal Industries, Inc., a Tennessee corporation (“DeRoyal”), to sell and assign to DeRoyal assets and liabilities exclusively related to the business of providing products for automated, direct-to-drain medical fluid disposal, including the Company’s STREAMWAY® product line (the “Eagan Business”). These assets were operated by the Company’s wholly owned subsidiary, Skyline Medical Inc. and have reported in the Company’s Eagan reportable operating segment in these consolidated financial statements.

The purchased assets exclusively related to the Eagan Business included (a) inventories, prototypes, packaging, supplies, parts, and equipment of the Business; (b) trademarks, service marks, trade names, copyrights, trade secrets and know-how, patents and patent applications, and other intellectual property and related proprietary rights exclusively related to the Eagan Business; (c) books and records exclusively related to the Eagan Business, including all drawings, documentation, research and development files, device master records, design history files, validation data, test reports, manufacturing instructions and procedures, records and data; (d) permits, licenses, franchises, approvals, certifications, authorizations, and consents required to be obtained from Governmental Authorities; (e) contracts with customers; (f) furniture, fixtures, equipment, supplies and other tangible personal property; (g) real property leased by Seller and exclusively used in connection with the Eagan Business; and (h) cash and accounts receivable due within ninety (90) days after the Closing Date exclusively related to the Eagan Business. The total purchase price for the purchased assets was $625,000, plus the assumption of certain liabilities related to the Eagan Business including the lease for the office and warehouse space located at 2915 Commers Drive Suite 900 Eagan, MN 55121, accounts payable due within 90 days after the closing date, and contract liabilities associated with the Eagan Business. The APA included certain post-closing covenants customary for a transaction of this nature.

March 2025 Warrant Exercises

On March 25, 2025, certain of the Company’s warrant holders exercised 627,315 Series A Common Stock Purchase Warrants (the “Series A Warrants”) and 627,315 Series B Common Stock Purchase Warrants (the “Series B Warrants”) in exchange for a total of 1,254,630 shares of the Company’s common stock. Both the Series A Warrants and Series B Warrants were exercised at a price of $1.07, resulting in approximately $1.3 million of proceeds to the Company. The Series A Warrants and Series B Warrants were initially issued in a private placement to certain institutional and accredited investors in July 2024 and were registered on Registration Statement No. 333-281579, which was declared effective on August 23, 2024.

Note 14 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	43,595	47,664
Warrant [Member]
Antidilutive Securities (in shares)	2,750,429	1,806,589
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	16	16

Note 2 - Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2024

Disposal Groups, Including Discontinued Operations [Table Text Block]

	December 31, 2024		December 31, 2023
Assets:
Accounts receivable, net		34,853		56,056
Inventories		-		13,571
Prepaid expense and other assets		18,796		9,622
Total current assets of discontinued operations		53,649		79,249

Property and equipment, net		-		742,696
Intangibles, net		-		11,118
Lease right-of-use assets		-		130,264
Other long-term assets		-		18,587
Total assets of discontinued operations	$	53,649	$	981,914

Liabilities:
Accounts payable	$	-	$	7,964
Accrued expenses and other liabilities		75,731		94,345
Lease liability		89,040		72,530
Total current liabilities of discontinued operations		164,771		174,839

Lease liability – net of current portion		-		58,002
Total liabilities	$	164,771	$	232,841

	Year Ended December 31,
	2024			2023
Revenue	$	32,790		$	152,396
Cost of sales		3,295			25,328
Gross profit (loss) from discontinued operations		29,495			127,068

Operating expenses:
General and administrative expense		855,855			1,047,578
Operations expense		506,011			859,360
Sales and marketing expense		4,385			23,722
Loss on impairment of property and equipment		-			162,905
Total operating expenses		1,366,251			2,093,565
Total operating (loss) from discontinued operations		(1,336,756	)		(1,966,497	)
Loss on disposal of discontinued operations		(463,127	)		-
Other income (expense)		(4,300	)		91
Net (loss) from discontinued operations	$	(1,804,183	)	$	(1,966,406	)

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

Note 10 - Derivatives (Details Textual) - USD ($)	12 Months Ended
Note 10 - Derivatives (Details Textual) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Derivatives	$ 0	$ 1,376
Agent Warrants In Connection With March 2020 Private Placement [Member]
Derivatives	0	135
Derivative, Gain (Loss) on Derivative, Net	135	3,220
Agent Warrants Issued in Connection with May 2020 Offering [Member]
Derivatives	0	333
Derivative, Gain (Loss) on Derivative, Net	333	4,146
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivatives	0	908
Derivative, Gain (Loss) on Derivative, Net	$ 908	$ 5,091

Note 11 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Shares, options (in shares)	43,595
Shares, warrants (in shares)	2,750,429	1,806,589
Price, warrants (in dollars per share)	$ 8.92	$ 21.52
Minimum [Member]
Price, options (in dollars per share)	6.22
Price, warrants (in dollars per share)	1.07
Maximum [Member]
Price, options (in dollars per share)	17,250
Price, warrants (in dollars per share)	$ 125
Warrants 2019 [Member]
Shares, warrants (in shares)	3,168
Warrants 2019 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 125
Warrants 2019 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 125
Warrants 2020 [Member]
Shares, warrants (in shares)	65,586
Warrants 2020 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 36
Warrants 2020 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 59.84
Warrants 2021 [Member]
Shares, warrants (in shares)	603,353
Warrants 2021 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 16
Warrants 2021 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 48.75
Warrants 2022 [Member]
Shares, warrants (in shares)	95,020
Warrants 2022 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 14
Warrants 2022 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 15
Warrants 2023 [Member]
Shares, warrants (in shares)	0
Warrants 2023 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 0
Warrants 2023 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 0
Warrants 2024 [Member]
Shares, warrants (in shares)	1,983,302
Warrants 2024 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 1.07
Warrants 2024 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 1.65
Stock Options 2015 [Member]
Shares, options (in shares)	12
Stock Options 2015 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 30.8
Stock Options 2015 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 17,250
Stock Options 2016 [Member]
Shares, options (in shares)	276
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 30.8
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 850
Stock Options 2017 [Member]
Shares, options (in shares)	10,353
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 30.8
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 420
Stock Options 2018 [Member]
Shares, options (in shares)	2,893
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 30.8
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 226
Stock Options 2019 [Member]
Shares, options (in shares)	13,932
Stock Options 2019 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 30.8
Stock Options 2019 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 158
Stock Options 2020 [Member]
Shares, options (in shares)	14,710
Stock Options 2020 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 14.65
Stock Options 2020 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 32.8
Stock Options 2021 [Member]
Shares, options (in shares)	540
Stock Options 2021 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 25
Stock Options 2021 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 26.6
Stock Options 2022 [Member]
Shares, options (in shares)	729
Stock Options 2022 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 7.7
Stock Options 2022 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 14.65
Stock Options 2023 [Member]
Shares, options (in shares)	150
Stock Options 2023 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 6.22
Stock Options 2023 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 6.22

Note 5 - Inventories - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Raw materials	$ 175,177	$ 227,110
Work-in-process	18,500	0
Finished goods	192,051	253,693
Total	$ 385,728	$ 480,803

Note 9 - Note Payable (Details Textual)	1 Months Ended
Note 9 - Note Payable (Details Textual)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Insurance Policy Financing June 2024 [Member]
Debt Instrument, Face Amount	$ 275,098
Debt Instrument, Number of Monthly Installment	10
Short-Term Debt, Percentage Bearing Fixed Interest Rate	8.00%
Notes Payable			$ 0
Insurance Policy Financing [Member]
Debt Instrument, Face Amount		$ 364,721
Debt Instrument, Number of Monthly Installment		10
Notes Payable				$ 150,408
Debt Instrument, Interest Rate, Stated Percentage		9.25%

Note 16 - Subsequent Events (Details Textual)						12 Months Ended
Note 16 - Subsequent Events (Details Textual)	Mar. 31, 2025 USD ($) shares	Mar. 25, 2025 USD ($) $ / shares shares	Mar. 14, 2025 USD ($)	Feb. 28, 2025 USD ($) shares	Feb. 18, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares	Jan. 01, 2025 USD ($) $ / shares	Jul. 25, 2024 $ / shares shares	May 03, 2024 $ / shares
Common Stock, Par or Stated Value Per Share \| $ / shares						$ 0.01	$ 0.01			$ 0.01
Proceeds from Issuance of Common Stock \| $						$ 4,960,562	$ 0
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 8.92	$ 21.52
Class of Warrant or Right, Exercised During Period \| shares						(958,117)
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares									958,117
Warrants and Rights Outstanding, Term									5 years
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares									958,117
Warrants and Rights Outstanding, Term									18 months
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 1.07
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 1.07
Subsequent Event [Member] \| Asset Purchase Agreement [Member]
Asset Acquisition, Consideration Transferred \| $			$ 625,000
Subsequent Event [Member] \| Registered Direct Offering, Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares					25,434
Warrants and Rights Outstanding, Term					5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price					125.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 1.875
Subsequent Event [Member] \| Series A Warrants [Member]
Class of Warrant or Right, Exercised During Period \| shares		627,315
Subsequent Event [Member] \| Series B Warrants [Member]
Class of Warrant or Right, Exercised During Period \| shares		627,315
Subsequent Event [Member] \| Series A and Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares		1,254,630
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 1.07
Proceeds from Warrant Exercises \| $		$ 1,300,000
Subsequent Event [Member] \| February 18, 2025 Offering [Member]
Stock Issued During Period, Shares, New Issues \| shares					363,336
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.01
Shares Issued, Price Per Share \| $ / shares					$ 1.5
Proceeds from Issuance of Common Stock \| $					$ 545,004
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds					7.00%
Sale of Stock, Management Fee, Percent of Gross Proceeds					1.00%
Professional Fees \| $					$ 15,000
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold					7.00%
Renovaro Acquisition [Member] \| Renovaro Preferred Stock [Member]
Business Acquisition, Equity Interest Issued and Issuable, Exchange Rate								1
Renovaro Acquisition [Member] \| Subsequent Event [Member]
Common Stock, Conditional Par Value, 30 Consecutive Days, Business Acquisition \| $ / shares								$ 4.5
Stock Issued During Period, Shares, Acquisitions (in shares) \| shares				467,290
Stock Issued During Period, Value, Acquisitions \| $				$ 500,000
Stock to Be Issued During Period, Shares, Acquisitions (in shares) \| shares	901,298
Stock to Be Issued During Period, Value, Acquisitions \| $	$ 964,389
Renovaro Acquisition [Member] \| Subsequent Event [Member] \| Renovaro [Member] \| Minimum [Member]
Minimum Fundraising Required \| $								$ 15,000,000
Renovaro Acquisition [Member] \| Subsequent Event [Member] \| Renovaro Preferred Stock [Member]
Business Acquisition, Equity Interest Issued and Issuable, Exchange Rate								1
Preferred Stock, Redemption Price Per Share (in dollars per share) \| $ / shares								$ 3
Preferred Stock, Convertible, Conversion Ratio								1

Note 6 - Property and Equipment, Net

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment Disclosure [Text Block]

NOTE 6 – PROPERTY AND EQUIPMENT, NET

The Company’s property and equipment, net consisted of the following:

	As of December 31, 2024			As of December 31, 2023
Computers, software, and office equipment	$	237,726		$	467,716
Leasehold improvements		306,961			306,961
Laboratory equipment		1,692,230			1,696,430
Warehouse and manufacturing equipment		139,763			133,285
Demo equipment		31,554			31,554
Total		2,408,234			2,635,946
Less: Accumulated depreciation		(2,038,764	)		(2,144,732	)
Total Property and equipment, net	$	369,470		$	491,214

Depreciation expense, recorded within general and administrative expenses of continuing operations, was $135,591 and $218,325 for the years ended December 31, 2024, and 2023, respectively.

No impairment charges related to property and equipment held and used in continuing operations were incurred during the years ended December 31, 2024, and 2023.

Note 11 - Stockholders' Equity, Stock Options and Warrants (Details Textual)				2 Months Ended	12 Months Ended
	Jul. 25, 2024 USD ($) $ / shares shares	Apr. 19, 2023 shares	Mar. 16, 2023 $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	May 03, 2024 USD ($) $ / shares
Common Stock, Par or Stated Value Per Share \| $ / shares					$ 0.01	$ 0.01	$ 0.01
Proceeds from Issuance of Common Stock \| $					$ 4,960,562	$ 0
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 8.92	$ 21.52
Class of Warrant or Right, Exercised During Period, Exercise Price \| $ / shares					$ 1.32
Payments of Stock Issuance Costs \| $					$ 870,960	$ (0)
Preferred Stock, Shares Authorized (in shares)					20,000,000	20,000,000
Common Stock, Shares Authorized (in shares)		200,000,000			200,000,000	200,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number					43,576	46,814
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares					$ 82.74	$ 83.61
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term					4 years 5 months 19 days	5 years 6 months 21 days
Class of Warrant or Right Number of Warrants Vested and Exercisable					2,750,429	1,806,589
Share-Based Payment Arrangement, Expense \| $					$ 1,118	$ 1,168
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount \| $					$ 0
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 1.07
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares					$ 125
Maximum [Member] \| Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)					3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)					10 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		20
Reverse Stock Split [Member] \| Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		2
Reverse Stock Split [Member] \| Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		25
Series F Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues			79,404
Preferred Stock, Shares Authorized (in shares)			80,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares			$ 0.01		$ 0.01
Preferred Stock Dividends, Shares Per Share (in shares)			1
Preferred Stock, Voting Rights Per Share (in shares)			1,000,000
Preferred Stock, Shares Outstanding		0
Series F Preferred Stock [Member] \| O 2023 Q1 Dividends [Member]
Dividends Payable, Date of Record			Mar. 27, 2023
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)					2,300,000	2,300,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares					$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding					79,246	79,246
Preferred Stock, Conversion Rate					16
The February 2021, June 2021, and May 2022 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	958,117
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 14
Class of Warrant or Right, Exercised During Period, Exercise Price \| $ / shares	$ 1.32
Proceeds from Warrant Exercises \| $	$ 1,265,000
Payments of Stock Issuance Costs \| $	$ 594,033
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	958,117
Warrants and Rights Outstanding, Term	5 years
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	958,117
Warrants and Rights Outstanding, Term	18 months
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1.07
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	67,068
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1.65
Warrants and Rights Outstanding, Term	5 years
Warrants or Rights, Commissions, Percent	7.00%
Warrants or Rights, Management Fee, Percent	1.00%
Warrants or Rights, Issuance Expenses \| $	$ 35,000
Warrants or Rights, Clearing Fees \| $	$ 15,950
Warrants or Rights, Placement Agent Fee, Percent	700.00%
Sales Agreement [Member]
Sale of Stock, Maximum Amount \| $							$ 3,696,000
Sale of Stock, Commissions, Percent							3.00%
Stock Issued During Period, Shares, New Issues				1,607,100
Shares Issued, Price Per Share \| $ / shares				$ 2.3
Proceeds from Issuance of Common Stock \| $				$ 3,696,000

Consolidated Statements of Stockholders' Equity - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] The February 2021, June 2021, and May 2022 Warrants [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series F Preferred Stock [Member]	Common Stock [Member] Sales Agreement [Member]	Common Stock [Member] The February 2021, June 2021, and May 2022 Warrants [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Sales Agreement [Member]	Additional Paid-in Capital [Member] The February 2021, June 2021, and May 2022 Warrants [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Sales Agreement [Member]	Retained Earnings [Member] The February 2021, June 2021, and May 2022 Warrants [Member]	Retained Earnings [Member]	Sales Agreement [Member]	The February 2021, June 2021, and May 2022 Warrants [Member]	Total
Balance (in shares) at Dec. 31, 2022			79,246	0			3,938,160
Balance at Dec. 31, 2022			$ 792	$ 0			$ 39,382			$ 175,503,634			$ (153,777,916)			$ 21,765,892
Vesting expense, net of forfeitures			0	0			0			2,038			0			2,038
Net loss			$ 0	$ 0			$ 0			0			(13,983,967)			(13,983,967)
Balance (in shares) at Dec. 31, 2023		79,246	79,246	0			4,062,853
Balance at Dec. 31, 2023		$ 792	$ 792	$ 0			$ 40,629			175,992,242			(167,761,883)			8,271,780
Shares issued to non-employees (in shares)			0	0			98,193
Shares issued to non-employees			$ 0	$ 0			$ 982			488,344			0			489,326
Series F Preferred Stock dividend (in shares)			0	79,404			0
Series F Preferred Stock dividend			$ 0	$ 794			$ 0						0			0
Series F Preferred Stock dividend										(794)
Reverse stock split round up to whole shares (in shares)			0	0			25,343
Reverse stock split round up to whole shares				$ 0			$ 253			(253)			0			0
Series F Preferred redemption (in shares)			0	(79,404)			0
Series F Preferred redemption			$ 0	$ (794)			$ 0			794			0			0
Share issuance to CFO for vesting of RSUs, net of repurchase to cover withholding tax (in shares)			0	0			1,157
Share issuance to CFO for vesting of RSUs, net of repurchase to cover withholding tax			$ 0	$ 0			$ 12			(1,521)			0			(1,509)
Issuance of shares and warrants (in shares)							38,923
Issuance of shares and warrants							$ 389			98,864			0			99,253
Vesting expense, net of forfeitures										1,143						1,143
Issuance of shares pursuant to At-The-Market financing, net of issuance costs (in shares)					1,607,100
Issuance of shares pursuant to At-The-Market financing, net of issuance costs					$ 16,071			$ 3,105,931			$ 0			$ 3,122,002
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs (in shares)	0					958,117
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs	$ 0					$ 9,581			$ 958,019			$ 0			$ 967,600
Net loss		$ 0					$ 0			0			(12,664,388)			(12,664,388)
Balance (in shares) at Dec. 31, 2024		79,246					6,666,993
Balance at Dec. 31, 2024		$ 792					$ 66,670			$ 180,156,199			$ (180,426,271)			$ (202,610)

Note 8 - Leases - Rent Obligation (Details)	Dec. 31, 2024 USD ($)
2025	$ 798,262
2026	803,724
2027	827,909
2028	139,022
Total lease payments	2,568,917
Less interest	(437,939)
Present value of lease liabilities	$ 2,130,978

Note 3 - Collaborative Arrangements and Contracts With Customers (Details Textual)	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Accounts Receivable, after Allowance for Credit Loss, Current		$ 745,566	$ 277,641
Accounts Receivable, Allowance for Credit Loss, Current		3,850	3,850
Contract with Customer, Liability		328,472	$ 307,958
Contract with Customer, Liability, Revenue Recognized		$ 74,766
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Number of Major Customers		3	2
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Concentration Risk, Percentage		19.00%	19.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer Two [Member]
Concentration Risk, Percentage		12.00%	11.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer Three [Member]
Concentration Risk, Percentage		11.00%
Revenue Benchmark [Member] \| Customer Concentration Risk [Member]
Number of Customers		1	1
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| Single Customer [Member]
Concentration Risk, Percentage	30.00%	28.00%
Cancer Research Horizons [Member] \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer		$ 0	$ 0

Note 10 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Derivative liability balance	$ 1,376	$ 13,833
Gain recognized to revalue derivative instrument at fair value	(1,376)	(12,457)
Derivative liability balance	$ 0	$ 1,376

Note 12 - Income Taxes - Reconciliation of Income Tax Benefit (Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Statutory federal income tax benefit	$ 2,280,643	$ 2,523,688
State tax benefit, net of federal taxes	406,186	515,593
State rate adjustment	(24,434)	(125,150)
Nondeductible/nontaxable items	(10,951)	121,708
NOL and deferred only adjustments	(571,133)	(59,913,532)
Other	(6,641)	(5,182)
Change in valuation allowance	(2,073,670)	56,882,875
Total income tax benefit	$ 0	$ 0

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Office Equipment [Member] | Minimum [Member]

Note 1 - Organization and Summary of Significant Accounting Policies (Details)

Dec. 31, 2024

Office Equipment [Member] | Maximum [Member]

3 years

Leasehold Improvements [Member] | Minimum [Member]

10 years

Leasehold Improvements [Member] | Maximum [Member]

1 year

^[1]

Manufacturing Tooling [Member] | Minimum [Member]

2 years

^[1]

Manufacturing Tooling [Member] | Maximum [Member]

3 years

Laboratory Equipment [Member] | Minimum [Member]

7 years

Laboratory Equipment [Member] | Maximum [Member]

4 years

10 years

Demo Equipment [Member]

3 years

[1]	Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Consolidated Balance Sheets - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 734,673	$ 8,728,660
Accounts receivable, net	745,566	277,641
Inventories	385,728	480,803
Prepaid expense and other assets	306,301	512,078
Current assets of discontinued operations	53,649	79,249
Total current assets	2,225,918	10,078,431
Property and equipment, net	369,470	491,214
Intangibles, net	210,113	241,339
Lease right-of-use assets	2,064,507	2,598,091
Other long-term assets	102,509	105,509
Non-current assets of discontinued operations	0	902,665
Total assets	4,972,517	14,417,249
Current liabilities:
Accounts payable	1,142,919	1,334,064
Note payable	0	150,408
Accrued expenses and other liabilities	1,407,987	1,542,948
Derivative liability	0	1,376
Contract liabilities	304,985	302,499
Lease liability	572,739	444,897
Current liabilities of discontinued operations	164,771	174,839
Total current liabilities	3,593,401	3,951,031
Other long-term liabilities	23,487	5,459
Lease liability – net of current portion	1,558,239	2,130,977
Non-current liabilities of discontinued operations	0	58,002
Total liabilities	5,175,127	6,145,469
Stockholders’ (deficit) equity:
Common stock, $.01 par value, 200,000,000 shares authorized, 6,666,993 and 4,062,853 shares outstanding as of December 31, 2024, and December 31, 2023, respectively	66,670	40,629
Additional paid-in capital	180,156,199	175,992,242
Accumulated deficit	(180,426,271)	(167,761,883)
Total stockholders’ (deficit) equity	(202,610)	8,271,780
Total liabilities and stockholders’ (deficit) equity	4,972,517	14,417,249
Series B Convertible Preferred Stock [Member]
Stockholders’ (deficit) equity:
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of December 31, 2024, and December 31, 2023	$ 792	$ 792

Consolidated Statements of Net Loss - USD ($)	12 Months Ended
Consolidated Statements of Net Loss - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 1,623,817	$ 1,627,697
Cost of sales	826,137	609,212
Gross profit	797,680	1,018,485
Operating expenses:
General and administrative expense	7,419,892	8,380,917
Operations expense	2,851,045	3,268,165
Sales and marketing expense	1,466,213	1,487,139
Total operating expenses	11,737,150	13,136,221
Total operating (loss)	(10,939,470)	(12,117,736)
Other income	89,367	152,685
Other expense	(11,478)	(64,967)
Gain on derivative instruments	1,376	12,457
Loss from continuing operations	(10,860,205)	(12,017,561)
Loss from discontinued operations	(1,804,183)	(1,966,406)
Net (loss)	$ (12,664,388)	$ (13,983,967)
Loss from continuing operations (in dollars per share)	$ (1.99)	$ (2.99)
Loss from discontinued operations (in dollars per share)	(0.33)	(0.49)
Net (loss) per common share, basic and diluted (in dollars per share)	$ (2.32)	$ (3.48)
Weighted average shares used in computation – basic and diluted (in shares)	5,453,632	4,014,848

Note 6 - Property and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Property, Plant, and Equipment Gross	$ 2,408,234	$ 2,635,946
Less: Accumulated depreciation	(2,038,764)	(2,144,732)
Total Property and Equipment, Net	369,470	491,214
Office Equipment [Member]
Property, Plant, and Equipment Gross	237,726	467,716
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	306,961	306,961
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	1,692,230	1,696,430
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	139,763	133,285
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 31,554	$ 31,554

Note 12 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Year Ended December 31,
	2024			2023
Statutory federal income tax benefit	$	2,280,643		$	2,523,688
State tax benefit, net of federal taxes		406,186			515,593
State rate adjustment		(24,434	)		(125,150	)
Nondeductible/nontaxable items		(10,951	)		121,708
NOL and deferred only adjustments		(571,133	)		(59,913,532	)
Other		(6,641	)		(5,182	)
Change in valuation allowance		(2,073,670	)		56,882,875
Total income tax benefit	$	-		$	-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31, 2024			December 31, 2023
Deferred tax assets:
Compensation accruals	$	42,893		$	87,131
Accruals and reserves		191,804			204,083
Deferred revenue		80,005			36,169
Charitable contribution carryover		1,742			1,724
Derivatives		-			349
Intangibles		696,622			852,414
Capitalized R&D		1,016,330			919,789
Depreciation		-			59,511
Lease liabilities		551,917			703,026
NQSO compensation		542,609			627,997
NOL and credits		24,479,583			21,737,285
Total deferred tax assets		27,603,505			25,229,478

Deferred tax liabilities:
Depreciation		(31,863	)		-
Lease right-of-use assets		(513,256	)		(691,119	)
Total deferred tax liabilities		(545,119	)		(691,119	)

Net deferred tax assets		27,058,386			24,538,359
Less: valuation allowance		(27,058,386	)		(24,538,359	)
Total	$	-		$	-

Note 4 - Fair Value Measurements

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Text Block]

NOTE 4 – FAIR VALUE MEASUREMENTS

The following table summarizes the Company’s fair value hierarchy for its assets and liabilities measured at fair value on a recurring basis:

December 31, 2024	Fair Value		Level 1		Level 2		Level 3
Assets:
Money market funds	$	300,000	$	300,000	$	-	$	-

Liabilities:
Derivatives	$	-	$	-	$	-	$	-

December 31, 2023	Fair Value		Level 1		Level 2		Level 3
Liabilities:
Derivatives	$	1,376	$	-	$	-	$	1,376

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Note 3 - Collaborative Arrangements and Contracts With Customers

12 Months Ended

Dec. 31, 2024

Collaborative Arrangement Disclosure [Text Block]

NOTE 3 – COLLABORATIVE ARRANGEMENTS AND CONTRACTS WITH CUSTOMERS

Collaboration Agreement with Cancer Research Horizons

On March 16, 2023, the Company entered into a Collaboration Agreement (the “CRH Agreement”) with Cancer Research Horizons (“CRH”), pursuant to which the Company used its PEDAL technology to evaluate CRH pre-clinical drug inhibitors of Glutaminase to determine which cancer types and patient populations were most likely to respond to treatment with those compounds (the “Project”). Under the CRH Agreement, both parties retained rights to their respective background intellectual property. Rights to reports, findings, supporting data, and materials (“Project Intellectual Property”) that were generated by the Company pursuant to its performance under the CRH Agreement vested exclusively in CRH. Each party funded its own participation in the Project. Costs incurred to participate in the CRH Agreement were recorded in Cost of sales in the Company’s Consolidated Statement of Net Loss for the year ended December 31, 2023.

Pursuant to the CRH Agreement, the Company shall receive a percentage of net revenue, as defined in the agreement, received by CRH for the commercialization of the CRH Candidates and any CRH Derivatives (each as defined in the CRH Agreement). The percentage of net revenue varies depending on the stage of development. The revenue sharing fees represent variable consideration, which is measured using the expected value method under ASC 606, Revenue from Contracts with Customers based on the actual net revenues earned by CRH under Relevant Transfer Agreements (as defined in the CRH Agreement) relating to the CRH Candidates and CRH Derivatives. Due to the uncertainty associated with the timing and amount of revenue sharing fees, the Company concluded that the revenue sharing fees should be fully constrained until such time that Relevant Transfer Agreements have been entered and net revenues have been earned. These estimates will be reassessed at each reporting period. During the years ended December 31, 2024, and 2023, the Company recognized no revenue under the CRH Agreement.

Contracts with Customers and Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2024, and 2023, accounts receivable totaled $745,566 and $277,641, respectively. The allowance for accounts receivable balance was $3,850 as of both December 31, 2024, and 2023.

As of December 31, 2024, accounts receivable from three customers represented 19%, 12%, and 11% of the Company’s total accounts receivable, respectively. As of December 31, 2023, accounts receivable from two customers represented 19% and 11% of the Company’s total accounts receivable, respectively.

During the year ended December 31, 2024, revenues from a single customer were 28% of the Company’s total revenue. During the year ended December 31, 2023, revenues from a single customer were 30% of the Company’s total revenue.

Advance payments received in excess of revenues recognized are classified as contract liabilities until such time as the revenue recognition criteria have been met. The Company’s contract liabilities, related primarily to development of 3D models and STREAMWAY maintenance plans, were $328,472 and $307,958 as of December 31, 2024, and 2023, respectively. During the year ended December 31, 2024, the Company recognized revenue of $74,766 from contract liabilities recorded as of December 31, 2023, primarily related to deposits for development of 3D models and STREAMWAY maintenance plans. The Company’s contract liabilities as of December 31, 2024, represent its remaining performance obligations. The Company’s long-term contract liabilities are reported in Other long-term liabilities in the consolidated balance sheets.

Note 12 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Compensation accruals	$ 42,893	$ 87,131
Accruals and reserves	191,804	204,083
Deferred revenue	80,005	36,169
Charitable contribution carryover	1,742	1,724
Derivatives	0	349
Intangibles	696,622	852,414
Capitalized R&D	1,016,330	919,789
Depreciation	0	59,511
Lease liabilities	551,917	703,026
NQSO compensation	542,609	627,997
NOL and credits	24,479,583	21,737,285
Total deferred tax assets	27,603,505	25,229,478
Depreciation	(31,863)	0
Lease right-of-use assets	(513,256)	(691,119)
Total deferred tax liabilities	(545,119)	(691,119)
Net deferred tax assets	27,058,386	24,538,359
Less: valuation allowance	(27,058,386)	(24,538,359)
Total	$ 0	$ 0

Note 11 - Stockholders' Equity, Stock Options and Warrants

12 Months Ended

Dec. 31, 2024

Equity [Text Block]

NOTE 11 – STOCKHOLDERS’ EQUITY, STOCK OPTIONS AND WARRANTS

At The Market Offering

On May 3, 2024, the Company entered into an ATM Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), to sell shares of the Company’s common stock, par value $0.01 per share (the “Shares”), having an aggregate sales price of up to $3,696,000, from time to time, through an “at the market offering” program pursuant to which Wainwright acted as sales agent. Subject to the terms and conditions of the Sales Agreement, Wainwright was permitted to sell the Shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Under the Sales Agreement, Wainwright was entitled to compensation for its services of 3.0% of the gross sales price of all shares sold through Wainwright under the Sales Agreement. As of June 30, 2024, the Company sold 1,607,100 shares of common stock at an average price of approximately $2.30 per share, resulting in aggregate gross proceeds of approximately $3,696,000. No further shares are available to be sold under the Sales Agreement.

Warrant Inducement Transaction

On July 25, 2024, the Company entered into definitive agreements with certain of its existing warrant holders for the exercise of warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The gross proceeds to the Company from the exercise of the existing warrants were approximately $1,265,000, prior to deducting placement agent fees and transaction expenses payable by the Company. The reduction of the exercise price represented a modification to the existing warrants, which was recognized as an equity issuance cost of $594,033 charged against the proceeds of the offering.

In consideration for the immediate cash exercise of the warrants, the Company concurrently issued to the warrant holders new unregistered Series A warrants to purchase up to 958,117 shares of common stock (the “Series A Warrants”) and new Series B warrants to purchase up to 958,117 shares of common stock (the “Series B Warrants”). The Series A Warrants and the Series B Warrants have an exercise price of $1.07 per share and are exercisable immediately upon issuance. The Series A Warrants have a term equal to five years from the date of issuance, and the Series B Warrants have a term equal to 18 months from the date of issuance.

The transactions described above closed on July 26, 2024. Wainwright acted as the exclusive placement agent for the above-mentioned transactions. The Company paid Wainwright as consideration (i) an aggregate cash fee equal to 7.0% of the gross proceeds from the exercise of the existing warrants, (ii) a management fee equal to 1.0% of the aggregate gross proceeds from the exercise of the existing warrants, (iii) $35,000 for expenses, and (iv) $15,950 for clearing fees. Additionally, the Company issued to Wainwright (or its designees) as compensation, warrants to purchase up to 67,068 shares of common stock of the Company (equal to 7.0% of the aggregate number of existing warrants exercised in the offering) (the “Warrant Inducement Placement Agent Warrants”). The Warrant Inducement Placement Agent Warrants have a term of five years from the closing of the offering and an exercise price of $1.65 per share.

Series F Preferred Stock Dividend and Reverse Stock Split

On March 16, 2023, the Board of Directors of the Company authorized the issuance of 80,000 shares of Series F Preferred Stock, par value $0.01 per share.

On March 16, 2023, the Board of Directors of the Company declared a dividend of one one-thousandth of a share of Series F Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held on record as of March 27, 2023. 79,404 shares of Series F Preferred Stock were issued pursuant to the stock dividend. Each share of Series F Preferred Stock entitled the holder thereof to 1,000,000 votes per share to vote together with the outstanding shares of common stock of the Company as a single class to adopt an amendment to the Company’s Certificate of Incorporation to affect a reverse stock split.

On April 19, 2023, the Company completed a one-for-twenty reverse stock split that was effective for trading purposes on April 24, 2023. No fractional shares were issued as a result of the reverse stock split. Any fractional shares that would otherwise have resulted from the reverse stock split were rounded up to the next whole number. The number of authorized shares of common stock under the Company’s certificate of incorporation, as amended, remained unchanged at 200,000,000 shares. All numbers of shares and per-share amounts in this report have been adjusted to reflect the reverse split. Proportionate reductions were made to the number of shares of common stock reserved for future issuance under our 2012 Equity Incentive Plan and the number of shares of common stock that may be issued upon exercise or vesting of outstanding equity incentive awards and warrants, and proportionate increases were made to the exercise price or share-based performance criteria, if any, applicable to such awards and warrants.

Redemption of Series F Preferred Stock

On April 17, 2023, the Company convened a special meeting of stockholders, which was adjourned due to the lack of a quorum and reconvened on April 19, 2023 (the “Special Meeting”), at which the Company’s stockholders approved a proposal to amend the Company’s certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-25, with such ratio to be determined by the Company’s Board of Directors (the “Reverse Split Proposal”). All shares of Series F Preferred Stock that were not present in person or by proxy at the Special Meeting as of immediately prior to the opening of the polls (the “Initial Redemption Time”) were automatically redeemed (the “Initial Redemption”). All outstanding shares of Series F Preferred Stock that were not redeemed pursuant to the Initial Redemption were redeemed automatically upon the approval by the Company’s stockholders of the Reverse Split Proposal (the “Subsequent Redemption” and, together with the Initial Redemption, the “Redemption”). Both the Initial Redemption and the Subsequent Redemption occurred on April 19, 2023. As a result, no shares of Series F Preferred Stock remain outstanding.

Series B Convertible Preferred Stock

As of December 31, 2024, and 2023, there were 79,246 shares of Series B Convertible Preferred Stock outstanding. The conversion rate of Series B Convertible Preferred Stock to Common Stock is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations, or similar events. The 79,246 shares of Series B Convertible Preferred Stock outstanding at December 31, 2024 were convertible to 16 shares of common stock. In addition, the Series B Convertible Preferred Stock will automatically convert into shares of common stock upon the occurrence of a fundamental transaction, as described in the certificate of designations for the Series B Convertible Preferred Stock including mergers, sales of the company’s assets, changes in control and similar transactions. The Series B Convertible Preferred Stock is not convertible by the holder of such preferred stock to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% of the common stock of the Company. The Series B Convertible Preferred Stock has no voting rights, except for the right to approve certain amendments to the certificate of designations or similar actions. With respect to payment of dividends and distribution of assets upon liquidation or dissolution or winding up of the Company, the Series B Convertible Preferred Stock shall rank equal to the common stock of the Company. No sinking fund has been established for the retirement or redemption of the Series B Convertible Preferred Stock.

Equity Incentive Plan

On December 30, 2024, the Company’s stockholders approved the 2024 Equity Incentive Plan (the “2024 Plan”) at the Company’s Annual Meeting of Stockholders and the 2024 Plan became effective. The 2024 Plan allows for the issuance of non-statutory stock options and incentive stock options, stock appreciation rights, stock awards, restricted stock, restricted stock units, and performance awards to employees, directors, and consultants of the Company, where permitted under the plan. Due to the approval of the 2024 Plan, no new awards will be granted under the Company’s Amended and Restated 2012 Stock Incentive Plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options outstanding under this plan have a contractual life of ten years.

ASC 718, Compensation – Stock Compensation (“ASC 718”), requires that a company that issues equity as compensation record compensation expense that corresponds to the estimated cost of those equity grants. ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means.

VALUATION AND ACCOUNTING FOR STOCK OPTIONS AND WARRANTS

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term.

The fair value of each stock option grant was estimated on the grant date using the Black-Scholes option valuation model with the following assumptions:

	Year Ended December 31,
	2024		2023
	Stock Options
Expected dividend yield		-		0.0%
Expected stock price volatility		-		90.8% –98.2%
Risk-free interest rate		-		3.38% –3.95%
Expected life		-	10 years
	Warrants
Expected dividend yield		0.0%		-
Expected stock price volatility		97.3%		-
Risk-free interest rate		4.06% –4.58%		-
Expected life		1.5 – 5 years		-

STOCK OPTIONS AND WARRANTS GRANTED BY THE COMPANY

The following summarizes transactions for stock options and warrants for the period indicated:

	Stock Options					Warrants
	Number of Shares			Average Exercise Price		Number of Shares			Average Exercise Price
Outstanding as of December 31, 2023		47,664		$	82.23		1,806,589		$	21.52

Issued		-			-		1,983,302			1.09
Forfeited		(309	)		5.04		-			-
Expired		(3,760	)		83.05		(81,345	)		37.90
Exercised		-			-		(958,117	)		1.32
Outstanding as of December 31, 2024		43,595		$	82.70		2,750,429		$	8.92

As of December 31, 2024, 43,576 stock options were fully vested and currently exercisable with a weighted average exercise price of $82.74 and a weighted average remaining term of 4.47 years. As of December 31, 2024, there were 2,750,429 warrants that were fully vested and currently exercisable.

As of December 31, 2023, 46,814 stock options were fully vested and currently exercisable with a weighted average exercise price of $83.61 and a weighted average remaining term of 5.56 years. As of December 31, 2023, there were 1,806,589 warrants that were fully vested and currently exercisable.

Stock-based compensation expense, net of forfeitures, recognized for the years ended December 31, 2024, and 2023, was $1,118 and $1,168, respectively. Stock-based compensation expense is recorded within each of the captions comprising Operating expenses from continuing operations. The Company has no unrecognized compensation expense related to unvested stock options that is expected to be recognized after December 31, 2024.

The following summarizes the status of options and warrants outstanding as of December 31, 2024:

Range of Exercise Prices	Shares		Weighted Average Remaining Life
Options
$6.22 –8.47		810		7.92
$14.65 –25.00		12,158		5.97
$26.20 –32.80		14,223		3.90
$52.20 –17,250.00		16,404		3.69
Total		43,595

Warrants:
$1.07 –1.65		1,983,302		2.88
$14.00 –25.00		462,336		0.14
$27.40 –40.00		226,448		3.26
$43.75 –125.00		78,343		1.03
Total		2,750,429

Stock options and warrants expire on various dates from February 2024 to July 2033.

The following table is the listing of outstanding stock options and warrants as of December 31, 2024, by year of grant:

Stock Options:

Year	Shares		Range of Exercise Prices
2015		12	$	30.80	–	$	17,250.00
2016		276		30.80	–		850.00
2017		10,353		30.80	–		420.00
2018		2,893		30.80	–		226.00
2019		13,932		30.80	–		158.00
2020		14,710		14.65	–		32.80
2021		540		25.00	–		26.60
2022		729		7.70	–		14.65
2023		150		6.22	–		6.22
Total		43,595	$	6.22	–	$	17,250.00

Warrants:

Year	Shares		Range of Exercise Prices
2019		3,168	$	125.00	–	$	125.00
2020		65,586		36.00	–		59.84
2021		603,353		16.00	–		48.75
2022		95,020		14.00	–		15.00
2023		-		-	–		-
2024		1,983,302		1.07	–		1.65
Total		2,750,429	$	1.07	–	$	125.00

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Note 13 - Retirement Savings Plan

12 Months Ended

Dec. 31, 2024

Retirement Benefits [Text Block]

NOTE 13 – RETIREMENT SAVINGS PLAN

The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. During 2024 and 2023, the Company matched 100% of the employee’s contribution up to 4.0% of their earnings. Employer contributions were $125,328 and $192,499 in 2024 and 2023, respectively. There were no discretionary contributions to the plan in 2024 and 2023.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Note 1 - Organization and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2024

Significant Accounting Policies [Text Block]

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

●

Eagan segment: produced the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

Going Concern

NASDAQ Notice of Non-Compliance

Principles of Consolidation

Discontinued Operations

Use of Estimates

Cash

Receivables

Concentration of Credit Risk

Fair Value Measurements

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis.

Property and Equipment

	Years
Computers, software, and office equipment	3	-	10
Leasehold improvements (1)	1	-	2
Manufacturing tooling	3	-	7
Laboratory equipment	4	-	10
Demo equipment		3

(1)

Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Finite-lived Intangible Assets

Long-lived Assets

Leases

Collaboration Arrangements

Revenue Recognition

Revenues from Services

Revenues from Product Sales

Royalty Revenue and Variable Consideration

Warranty

Contract Balances

Practical Expedients

Stock-Based Compensation

Research and Development

Income Taxes

Tax years after 2004 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

Risks and Uncertainties

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

Note 12 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
Note 12 - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Income Tax Expense (Benefit)	$ 0	$ 0
Tax Credit Carryforward, Valuation Allowance	57,446,259
Unrecognized Tax Benefits	0
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	99,731,593	86,840,808
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	11,885,918	43,354,286
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	87,845,675	43,486,522
Operating Loss Carryforwards, Valuation Allowance	23,121,946	20,558,729
Change in Operating Loss Carryforwards	237,816,096
Change in Deferred Tax Assets Attributable to Operating Losses	49,941,380
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	55,735,192	59,425,348
Operating Loss Carryforwards, Valuation Allowance	3,936,440	$ 3,979,630
Change in Operating Loss Carryforwards	178,311,455
Change in Deferred Tax Assets Attributable to Operating Losses	$ 7,344,800

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2024
Trading Arrangements, by Individual [Table]
Material Terms of Trading Arrangement [Text Block]	ITEM 9B. OTHER INFORMATION. None.
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 15 - Segments - Segments (Details) - USD ($)	12 Months Ended
Note 15 - Segments - Segments (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Revenue	$ 1,623,817	$ 1,627,697
Assets	4,918,868	13,435,335
Cost of sales	826,137	609,212
Depreciation and amortization	162,079	244,788
Gross profit	797,680	1,018,485
Expenditures for additions to long-lived assets	9,510	47,550
General and administrative expenses	7,419,892	8,380,917
Operations expenses	2,851,045	3,268,165
Sales and marketing expenses	1,466,213	1,487,139
Total operating (loss)	(10,939,470)	(12,117,736)
Other segment items	79,265	100,175
Segment (loss)	(10,860,205)	(12,017,561)
Operating Segments [Member] \| Pittsburgh [Member]
Revenue	84,812	492,596
Assets	2,615,291	3,263,270
Cost of sales	78,285	195,105
Depreciation and amortization	124,939	207,658
Gross profit	6,527	297,491
Expenditures for additions to long-lived assets	3,032	7,424
General and administrative expenses	2,022,732	2,364,640
Operations expenses	2,234,501	2,443,316
Sales and marketing expenses	5	299
Total operating (loss)	(4,250,711)	(4,510,763)
Other segment items	(606)	6,857
Segment (loss)	(4,251,317)	(4,503,906)
Operating Segments [Member] \| Eagan [Member]
Revenue	1,539,005	1,135,101
Assets	1,410,090	1,390,031
Cost of sales	747,852	414,107
Depreciation and amortization	29,743	29,750
Gross profit	791,153	720,993
Expenditures for additions to long-lived assets	6,478	24,691
General and administrative expenses	184,095	518,017
Operations expenses	609,584	806,658
Sales and marketing expenses	633,015	364,697
Total operating (loss)	(635,541)	(968,379)
Other segment items	(9)	(902)
Segment (loss)	(635,550)	(969,281)
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Revenue	0	0
Assets	893,487	8,782,034
Cost of sales	0	0
Depreciation and amortization	7,397	7,381
Gross profit	0	0
Expenditures for additions to long-lived assets	0	15,437
General and administrative expenses	5,213,065	5,498,260
Operations expenses	6,960	18,192
Sales and marketing expenses	833,193	1,122,142
Total operating (loss)	(6,053,218)	(6,638,594)
Other segment items	79,880	94,220
Segment (loss)	$ (5,973,338)	$ (6,544,374)

Note 10 - Derivatives (Tables)

12 Months Ended

Dec. 31, 2024

Schedule of Derivative Liabilities at Fair Value [Table Text Block]

Derivative liability balance at December 31, 2022	$	13,833
Gain recognized to revalue derivative instrument at fair value		(12,457	)
Derivative liability balance at December 31, 2023	$	1,376
Gain recognized to revalue derivative instrument at fair value		(1,376	)
Derivative liability balance at December 31, 2024	$	-

Note 8 - Leases (Tables)

12 Months Ended

Dec. 31, 2024

Lease, Cost [Table Text Block]

	December 31, 2024			December 31, 2023
Weighted average remaining lease term – operating leases in years		3.14			4.11
Weighted average discount rate – operating leases		13	%		13	%

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

2025		798,262
2026		803,724
2027		827,909
2028		139,022
Total lease payments		2,568,917
Less: interest		(437,939	)
Present value of lease liabilities	$	2,130,978

Note 10 - Derivatives

12 Months Ended

Dec. 31, 2024

Derivative Instruments and Hedging Activities Disclosure [Text Block]

NOTE 10 – DERIVATIVES

Certain warrants issued to placement agents in 2020 were determined to be a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the fair value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock. Therefore, the warrants were classified as a liability.

The fair value of the placement agent warrants issued in connection with the March 2020 private placement was determined to be $0 and $135 as of December 31, 2024, and 2023, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of $135 and $3,220 during the years ended December 31, 2024, and 2023, respectively. The placement agent warrants expire in March 2025.

The fair value of the placement agent warrants issued in connection with the May 2020 offering of securities was determined to be $0 and $333 as of December 31, 2024, and 2023, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of $333 and $4,146 during the years ended December 31, 2024, and 2023, respectively. The placement agent warrants expire in May 2025.

The placement agent warrants issued in connection with the June 2020 warrant exercise and issuance had a fair value of $0 and $908 as of December 31, 2024, and 2023, respectively. The Company recorded gains on the change in fair value of the placement agent warrants of $908 and $5,091 during the years ended December 31, 2024, and 2023, respectively. The placement agent warrants expire in June 2025.

The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above.

Derivative liability balance at December 31, 2022	$	13,833
Gain recognized to revalue derivative instrument at fair value		(12,457	)
Derivative liability balance at December 31, 2023	$	1,376
Gain recognized to revalue derivative instrument at fair value		(1,376	)
Derivative liability balance at December 31, 2024	$	-

Note 11 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Shares, options (in shares)	43,595
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8.92	$ 21.52
Shares, warrants (in shares)	2,750,429	1,806,589
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.07
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	125
Stock Options One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	6.22
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 8.47
Shares, options (in shares)	810
Weighted average remaining life, options (Year)	7 years 11 months 1 day
Stock Options Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 14.65
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 25
Shares, options (in shares)	12,158
Weighted average remaining life, options (Year)	5 years 11 months 19 days
Stock Options Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 26.2
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 32.8
Shares, options (in shares)	14,223
Weighted average remaining life, options (Year)	3 years 10 months 24 days
Stock Options Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 52.2
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 17,250
Shares, options (in shares)	16,404
Weighted average remaining life, options (Year)	3 years 8 months 8 days
Warrant One [Member]
Shares, warrants (in shares)	1,983,302
Weighted average remaining life, warrants (Year)	2 years 10 months 17 days
Warrant One [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.07
Warrant One [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.65
Warrant Two [Member]
Shares, warrants (in shares)	462,336
Weighted average remaining life, warrants (Year)	1 month 20 days
Warrant Two [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 14
Warrant Two [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 25
Warrant Three [Member]
Shares, warrants (in shares)	226,448
Weighted average remaining life, warrants (Year)	3 years 3 months 3 days
Warrant Three [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 27.4
Warrant Three [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 40
Warrant Four [Member]
Shares, warrants (in shares)	78,343
Weighted average remaining life, warrants (Year)	1 year 10 days
Warrant Four [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 43.75
Warrant Four [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 125

Note 11 - Stockholders' Equity, Stock Options and Warrants - Stock Offerings (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	0.00%
Risk-free interest rate	0.00%
Expected life (years) (Year)		10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants measurement input	0	0
Measurement Input, Price Volatility [Member]
Warrants measurement input	0.973	0
Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input		0
Measurement Input, Expected Term [Member]
Warrants measurement input		0
Minimum [Member]
Expected stock price volatility		90.80%
Risk-free interest rate		3.38%
Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	0.0406
Minimum [Member] \| Measurement Input, Expected Term [Member]
Warrants measurement input	1.5
Maximum [Member]
Expected stock price volatility		98.20%
Risk-free interest rate		3.95%
Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	0.0458
Maximum [Member] \| Measurement Input, Expected Term [Member]
Warrants measurement input	5

Note 15 - Segments

12 Months Ended

Dec. 31, 2024

Segment Reporting Disclosure [Text Block]

NOTE 15 – SEGMENTS

The Company has determined its operating segments in accordance with ASC 280, Segment Reporting. Factors used to determine the Company’s reportable segments include the availability of separate financial statements, the existence of locally based leadership across geographic regions, the economic factors affecting each segment, and the evaluation of operating results at the segment level. The Company’s Chief Operating Decision Maker (“CODM”), its chief executive officer, allocates the Company’s resources for each of the operating segments and evaluates their relative performance based on gross profit, operating loss, and net loss. Operating expenses are disaggregated by department for purposes of evaluating each segment’s performance. Each operating segment listed below has separate financial statements and locally based leadership that are evaluated based on the results of their respective segments. It should be noted that the operating segments below have different products and services.

The Company has two reportable segments, which have been delineated by location and business area:

●

Eagan segment: produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal.

As described in Note 2, the Company’s former Birmingham operating segment met the criteria to be reported as discontinued operations during the third quarter of 2024. As such, the former Birmingham segment is excluded from the tables below, which only reflect continuing operations for all periods presented.

See discussion of revenue recognition in Note 1 – Organization and Summary of Significant Accounting Policies for a description of the products and services recognized in each segment. All revenues are earned from external customers.

The tables below summarize the Company’s segment reporting as of and for the years ended December 31, 2024, and 2023.

	Year Ended December 31, 2024
	Pittsburgh			Eagan			Corporate			Total
Revenue	$	84,812		$	1,539,005		$	-		$	1,623,817
Cost of sales		78,285			747,852			-			826,137
Gross profit		6,527			791,153			-			797,680
General and administrative expenses		2,022,732			184,095			5,213,065			7,419,892
Operations expenses		2,234,501			609,584			6,960			2,851,045
Sales and marketing expenses		5			633,015			833,193			1,466,213
Total operating (loss)		(4,250,711	)		(635,541	)		(6,053,218	)		(10,939,470	)
Other segment items		(606	)		(9	)		79,880			79,265
Segment (loss)	$	(4,251,317	)	$	(635,550	)	$	(5,973,338	)	$	(10,860,205	)

	December 31, 2024
	Pittsburgh		Eagan		Corporate		Total
Assets	$	2,615,291	$	1,410,090	$	893,487	$	4,918,868
Depreciation and amortization		124,939		29,743		7,397		162,079
Expenditures for additions to long-lived assets		3,032		6,478		-		9,510

	Year Ended December 31, 2023
	Pittsburgh			Eagan			Corporate			Total
Revenue	$	492,596		$	1,135,101		$	-		$	1,627,697
Cost of sales		195,105			414,107			-			609,212
Gross profit		297,491			720,993			-			1,018,485
General and administrative expenses		2,364,640			518,017			5,498,260			8,380,917
Operations expenses		2,443,316			806,658			18,192			3,268,165
Sales and marketing expenses		299			364,697			1,122,142			1,487,139
Total operating (loss)		(4,510,763	)		(968,379	)		(6,638,594	)		(12,117,736	)
Other segment items		6,857			(902	)		94,220			100,175
Segment (loss)	$	(4,503,906	)	$	(969,281	)	$	(6,544,374	)	$	(12,017,561	)

	December 31, 2023
	Pittsburgh		Eagan		Corporate		Total
Assets	$	3,263,270	$	1,390,031	$	8,782,034	$	13,435,335
Depreciation and amortization		207,658		29,750		7,381		244,788
Expenditures for additions to long-lived assets		7,424		24,691		15,437		47,550

Other segment items are comprised of other income, other expenses, and gain on derivative instruments. Other income primarily consists of interest income. Other expenses primarily consist of interest expense and, in the year ended December 31, 2023, losses on a note receivable deemed uncollectible.

In each of the years ended December 31, 2024, and 2023, substantially all the Company revenues were located or derived from operations in the United States. As of December 31, 2024, all the Company’s long-lived assets were located within the United States. During the year ended December 31, 2024, revenues of $459,369 reported in the Company’s Eagan operating segment were attributable to a single customer. As of December 31, 2024, accounts receivable due from this customer was $144,880. During the year ended December 31, 2023, revenues of $489,921 reported in the Company’s Pittsburgh segment were attributable to a single customer. As of December 31, 2023, accounts receivable due from this customer was $52,072.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Note 7 - Intangibles, Net - Estimated Future Amortization Expense (Details)	Dec. 31, 2024 USD ($)
2025	$ 26,489
2026	26,489
2027	26,489
2028	26,489
2029	26,489
Thereafter	77,669
Total	$ 210,113

Note 2 - Discontinued Operations

12 Months Ended

Dec. 31, 2024

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

NOTE 2 – DISCONTINUED OPERATIONS

On July 25, 2024, the Company’s Board of Directors approved a plan to implement a strategic cost savings initiative, primarily related to the Company’s Birmingham laboratory. In August 2024, the Company explored options for the leased Birmingham laboratory and office space, including potential sublease arrangements.

In September 2024, the Company transferred certain pieces of computer hardware with alternative use to the Pittsburgh laboratory, while the rest of the laboratory equipment and inventories from the Birmingham laboratory were marketed for sale and the related product and service lines were discontinued. The Company executed a sales agreement for all remaining laboratory equipment and inventories from the Birmingham laboratory and all items were removed from the laboratory premises as of September 30, 2024. As of September 30, 2024, the Company vacated and ceased use of the Birmingham laboratory and office space. The Company’s lease continues through August 2025.

The Company concluded that, in aggregate, the disposal of these assets comprising the former Birmingham operating segment met the criteria for discontinued operations presentation in the third quarter of 2024. As a result, the former Birmingham operating segment has been reclassified to discontinued operations in these consolidated financial statements for all periods presented.

The following table presents a reconciliation of the carrying amounts of the major classes of assets and liabilities to the current assets and liabilities of discontinued operations as presented in the Company’s consolidated balance sheets:

	December 31, 2024		December 31, 2023
Assets:
Accounts receivable, net		34,853		56,056
Inventories		-		13,571
Prepaid expense and other assets		18,796		9,622
Total current assets of discontinued operations		53,649		79,249

Property and equipment, net		-		742,696
Intangibles, net		-		11,118
Lease right-of-use assets		-		130,264
Other long-term assets		-		18,587
Total assets of discontinued operations	$	53,649	$	981,914

Liabilities:
Accounts payable	$	-	$	7,964
Accrued expenses and other liabilities		75,731		94,345
Lease liability		89,040		72,530
Total current liabilities of discontinued operations		164,771		174,839

Lease liability – net of current portion		-		58,002
Total liabilities	$	164,771	$	232,841

The following table provides details about the major classes of line items constituting the loss from discontinued operations presented in the Company’s consolidated statements of net loss:

	Year Ended December 31,
	2024			2023
Revenue	$	32,790		$	152,396
Cost of sales		3,295			25,328
Gross profit (loss) from discontinued operations		29,495			127,068

Operating expenses:
General and administrative expense		855,855			1,047,578
Operations expense		506,011			859,360
Sales and marketing expense		4,385			23,722
Loss on impairment of property and equipment		-			162,905
Total operating expenses		1,366,251			2,093,565
Total operating (loss) from discontinued operations		(1,336,756	)		(1,966,497	)
Loss on disposal of discontinued operations		(463,127	)		-
Other income (expense)		(4,300	)		91
Net (loss) from discontinued operations	$	(1,804,183	)	$	(1,966,406	)

The loss on disposal of discontinued operations represents the loss on impairment of assets sold, including laboratory equipment and inventories, and impairment of other non-current assets.

Note 9 - Note Payable

12 Months Ended

Dec. 31, 2024

Debt Disclosure [Text Block]

NOTE 9 – NOTE PAYABLE

In June 2024, the Company purchased director and officer insurance policies with a policy period ending June 2025 and financed $275,098 of its total premium by entering into a note payable with a finance provider that required ten monthly installment payments through April 2025. The note was secured by a first priority lien on the financed policies. The short-term note bore interest at an annual percentage rate of 8.00% over the life of the note. As of December 31, 2024, there was no outstanding balance on the note.

In June 2023, the Company purchased director and officer insurance policies with a policy period ending June 2024. In July 2023, the Company financed $364,721 of its total premium by entering into a note payable with a finance provider that required ten monthly installment payments through April 2024. The note was secured by a first priority lien on the financed policies. The short-term note bore interest at an annual percentage rate of 9.25% over the life of the note. As of December 31, 2023, the outstanding balance of the note was $150,408 including interest. The note was fully paid during the year ended December 31, 2024.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Note 13 - Retirement Savings Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 125,328	$ 192,499
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 15 - Segments (Details Textual)	12 Months Ended
Note 15 - Segments (Details Textual)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Number of Operating Segments	2
Number of Tumor Samples	150,000
Eagan [Member] \| Revenue from Contract with Customer, Segment Benchmark [Member] \| Customer Concentration Risk [Member]
Number of Customers	1
Eagan [Member] \| Revenue from Contract with Customer, Segment Benchmark [Member] \| Customer Concentration Risk [Member] \| One Individual [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 459,369
Eagan [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Number of Customers	1
Eagan [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| One Individual [Member]
Accounts Receivable, after Allowance for Credit Loss	$ 144,880
Pittsburgh [Member] \| Revenue from Contract with Customer, Segment Benchmark [Member] \| Customer Concentration Risk [Member]
Number of Customers		1
Pittsburgh [Member] \| Revenue from Contract with Customer, Segment Benchmark [Member] \| Customer Concentration Risk [Member] \| One Individual [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 489,921
Pittsburgh [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Number of Customers		1
Pittsburgh [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| One Individual [Member]
Accounts Receivable, after Allowance for Credit Loss		$ 52,072

Note 7 - Intangibles, Net (Tables)

12 Months Ended

Dec. 31, 2024